摘要
在体内直接表征肿瘤缺氧、酸中毒与代谢重编程之间的相互作用仍是一项重大的转化挑战。在此,我们在临床3 T系统上建立了一套可临床部署的同步PET/MRI工作流程,该流程结合了用于映射代谢通量的超极化13C MRI([1‐13C]丙酮酸)、用于探测细胞外pH的[1,5‐13C2,3,6,6,6‐D4]zymonic acid,以及用于定量缺氧的[18F]FMISO PET。招募患有肉瘤的家猫作为临床相关且具有比较性的疾病模型,形成了一个高度异质性的研究队列。所有模态均可成功应用,并首次实现了对家猫自发性肿瘤酸化的同步、配准映射,辅以代谢和缺氧成像。影像参数的相关性分析提供了对肿瘤间和肿瘤内异质性的多维评估,表明不同亚型具有不同的参数相关性指纹。该多参数方案为深入了解肉瘤的代谢程序提供了新见解,提示肿瘤酸化与缺氧及乳酸生成增加相耦合。此外,pH成像在评估肉瘤侵袭性和相关受试者结局方面显示出强大潜力。总之,这些结果建立了一套可转化部署的同步PET/MRI工作流程,用于肿瘤代谢和微环境的整合成像,支持将pH成像转化为患者分层和治疗监测的努力。
[内容请查看原文]
引言
癌细胞通常增加乳酸生成,因为代谢失调是癌症的标志[1]。Otto Warburg早期认识到,即使在氧气存在的情况下,糖酵解增强和乳酸形成也可能发生[2],然而缺氧信号对代谢通路具有多方面作用[3]。乳酸外排可导致细胞外空间酸化[4],而多种其他机制可进一步加剧这一过程。肿瘤酸性已被与增殖、转移和免疫逃逸相关联[5, 6, 7, 8]。在临床上,酸性具有相关性,因为它塑造抗肿瘤免疫[7],并可能代表一种通过微环境靶向调理策略可修饰的脆弱性[9]。总之,缺氧、乳酸相关代谢和细胞外pH构成了肿瘤生物学中关键的、相互关联的参数[10]。它们常被视为实体瘤紧密耦合的标志,若干影像学研究已评估了这些因素的两两组合[11, 12, 13, 14, 15, 16, 17, 18]。然而,据我们所知,尚未建立一种可在临床转化的、在同一成像会话中同时测量所有三项参数的方案。
混合PET/MRI提供了一个转化平台,可将已建立的缺氧示踪剂如[18F]氟米索硝唑([18F]FMISO)[19]与新兴的分子磁共振成像(MRI)方法相结合。超极化13C MRI是一种新技术,已转化至人体研究[20],能够无辐射、无创地评估代谢通量[21],并且使用合适的探针还可实现pH敏感读出[22, 23, 24, 25]。正电子发射断层扫描(PET)与超极化13C MRI的整合已在临床前小型[26, 27, 28]和大型动物研究[29, 30, 31, 32]中得到证明,早期临床研究也正在涌现[33, 34]。然而,迄今为止,大多数PET-超极化13C联合研究集中于使用超极化[1‐13C]丙酮酸联合[18F]FDG PET对肿瘤代谢进行互补评估,而未直接涉及缺氧或pH。
一种稳健、无创的pH成像方法是尚未满足的临床需求。尽管在表征酸性肿瘤区域方面付出了大量努力,但测量组织细胞外pH的方法在临床实践和研究中尚未常规可用,限制了酸化模型的检验以及pH作为分层或治疗监测生物标志物的评估[24, 35, 36, 37]。此外,肿瘤异质性使得肿瘤微环境成像高度相关:缺氧、代谢和酸性可在同一病灶内显著变化,而序贯或分开测量使共定位和解读复杂化。
家猫的比较肿瘤学为转化提供了一条特别有趣的路径。猫的基础代谢率更接近人类(约为人类代谢率的2.5倍,而小鼠约为10倍)[38, 39],且自发产生的猫肉瘤提供了丰富的、临床管理的肿瘤模型。这些肿瘤发生于皮肤和结缔组织,历史上常与曾使用的疫苗及其佐剂相关(猫注射部位肉瘤)[40]。间叶性肿瘤是最常见的猫科癌症之一,在一项跨越四十余年的回顾性流行病学研究中表现出高比例的恶性[41]。重要的是,猫肉瘤与人肉瘤中报道的代谢特征相似,包括葡萄糖利用增加和丙酮酸向乳酸转化升高[42]。这种代谢重编程通常独立于缺氧[2, 43],而缺氧本身常存在于细胞密度高的实体致密肿瘤中。随后乳酸的外渗可导致细胞外空间酸化,从而促进免疫逃逸和增殖(图1A)。
[图:用于成像肿瘤微环境关键特征——代谢、缺氧、pH和细胞密度的研究流程。(A) 肿瘤 c]

在本研究中,我们在临床3 T PET/MRI系统上实施并评估了一种同步成像方案,该方案结合了使用[1,5‐13C2,3,6,6,6‐D4]酵酮酸[22, 44]的超极化13C磁共振波谱成像(MRSI)进行pH成像、使用[1‐13C]丙酮酸的超极化13C MRSI探测代谢,以及使用[18F]FMISO的PET缺氧成像,应用于猫肉瘤患者。我们报告了一种联合成像方法的可行性,该方法首次在自发性肉瘤中实现了空间分辨的pH mapping,并与缺氧和代谢通量图进行配准。我们进一步探索了这些参数在肿瘤间和单个肿瘤内的空间异质性。所提出的方案在临床相关环境中整合了三种常被提及的肿瘤标志的评估,从而支持对缺氧、代谢和pH之间关系的机制性评估,并为pH敏感成像生物标志物在诊断、分层和治疗监测中的转化开发提供信息。
[内容请查看原文]
结果
[内容请查看原文]
肿瘤形态学
共有17例活检确诊的恶性间叶性肿瘤患者(表S1)和1例良性神经纤维瘤患者纳入研究,并接受了完整的成像方案,包括超极化13C MRSI、PET和解剖成像(图1B,C)。成像期间采集的所有监测参数均未显示不良趋势,表明所有猫对注射和麻醉耐受良好(图S1)。成像前后血细胞计数和血清分析的相对比较,以及与参考范围的比较,显示成像相关方案和注射未引起相关不良血液学效应(图S2)。所有病灶在T1和T2加权图像上均表现为可识别但不总是边界清晰的病变。MRI未观察到额外的继发病灶或转移。若干肿瘤显示解剖异质性,由实性肿瘤组织区域和组织缺失区域(囊肿、坏死)组成,包括游离液体。因此,弥散加权成像(DWI)显示含液区域和实性组织区域分别具有高值和中等偏低值的表观弥散系数(ADC)(图2A)。全肿瘤ADC值似乎相对较高,但所有成像肿瘤的范围相似(图2B)。使用组织标记的肿瘤边缘和标准化修整方案,实现了肿瘤切片苏木精&伊红(H&E)组织形态学的配准。染色证实了组织异质性和空洞形成,可能由囊肿或大面积坏死区域所致(图2C)。
[图:通过DWI和组织病理学进行肿瘤表征。(A) 左:胸部区域的轴位解剖T2加权图像]

由经验丰富的兽医和人类病理学家对所有肿瘤进行详细分析,可将本研究中的肿瘤分类为:2例纤维肉瘤(FS)1级(G1)、7例FS G2、1例FS G3、3例未分化多形性肉瘤(UPS,简称多形性肉瘤)、1例血管肉瘤(HAS)、1例软骨肉瘤(CS)、1例骨肉瘤(OS)和1例“双形态肿瘤”(BMT)。对于后者,可观察到两个不同的形态学生长模式(GP)区域,但由于缺乏猫组织特异性标志物,无法基于H&E和免疫组织化学进行精确的亚型分类。根据兽医WHO分类标准[45],1例肿瘤切除标本最终被分类为良性神经纤维瘤(NF)。亚型特异性肿瘤形态的代表性图像总结于图2D。值得注意的是,所有恶性肿瘤均表现出相对较高的ADC值,且FS各级别之间无差异,而良性NF显示最低的ADC。
[内容请查看原文]
肿瘤酸化
使用[1,5‐13C2,3,6,6,6‐D4]酵酮酸的pH成像提供了足够的信号强度,使得在大多数成像肿瘤中能够以高空间覆盖率进行pH mapping。这揭示了酸化热点(图3A),其中平均pH酸化程度高达0.3个pH单位,而大部分肿瘤区域具有生理性pH。这些酸化热点表现为肿瘤中的酸化pH区室,可检测为酵酮酸C1共振的额外光谱峰(图3B)。
[图:体内pH成像揭示肿瘤酸化。(A) 从超极化MRSI采集重建的平均pH图]

由于与更高场强相比,3 T 下 pH 敏感性较低且光谱分辨率下降,相应的 C5 峰常常不可见[22]。额外的 pH 组分被归属于细胞外空间[22],而第一个组分来源于肿瘤血管。对不同肿瘤组绝对 pH 值的比较显示,随着 FS 分级升高,pH 值下降,且许多成像肿瘤的 pH 值比生理范围低最多 0.2 个 pH 单位,包括良性 NF(图3C)。最具侵袭性的 FS G3 平均 pH 低于 7.0。此外,将肿瘤 pH 与同一动物的健康组织 pH 进行比较,也显示肿瘤酸化(pH 7.30 ± 0.18)相较于肌肉 pH(配对 t 检验,pH 7.41 ± 0.11,p = 0.001,图3D)。然而,肌肉 pH 值在个体间也差异很大,且已知全身机体 pH 易受异氟烷麻醉影响[23]。为消除个体间变异(其可能取决于每日动物状态和麻醉条件的变化),从同一动物的相应肌肉 pH 中减去肿瘤 pH 值,以计算有效肿瘤酸化(Ac.)。此处选择肿瘤邻近肌肉作为组织 pH 参考,因为其 pH 值与血管区域 pH 值一致(图S3),但肌肉区域通常更靠近线圈并具有更好的信噪比。此处,不同分级的 FS 可显示高达 0.5 个 pH 单位的酸化(图3E),并呈 FS 分级越高酸化越强的趋势。骨源性肉瘤(CS、OS)也显示明显酸化,这与先前报道的发现一致[46]。值得注意的是,HAS 和良性 NF 未显示酸化,可能要么是由于血液的强缓冲作用,要么是由于非恶性。
[内容请查看原文]
肿瘤代谢
为探究代谢改变,进行了[1‐13C]丙酮酸的超极化 13C MRSI 及其与[1‐13C]乳酸的后继交换。丙酮酸(上)和乳酸(下)图像的时间序列显示了动态 MRSI 采集的前十帧,起始于中央血管中的明亮团注,随后中央肿瘤区域出现强丙酮酸和乳酸信号(图4A)。全肿瘤时间曲线(图4B)显示强丙酮酸团注及相应的乳酸 13C 标记。使用这些丙酮酸和乳酸时间曲线在体素基础上计算曲线下面积比(AUCr)图,可识别肿瘤区域内高代谢通量的热点(图4C)。有趣的是,与(图3A)中 pH 图的定性比较显示,酸化热点和代谢活跃热点的定位相似。在全肿瘤基础上比较 AUCr 值(图4D)揭示了亚型之间的差异,类似于 pH 成像的发现,并可能表明 FS 分级越高代谢活性越强。
[图:体内肿瘤代谢成像。(A)[1‐13C]丙酮酸的图像时间序列]pyruvate and [1‐ 13 C]lactate. The FS G2 shown as an]

UPS 显示最高的总体 AUCr 值,但也存在强烈的亚型内变异。CS 的 AUCr 值显著高于 OS。与酸化模式相似,HAS 和 NF 相对于其他亚型仅显示低代谢活性。
[内容请查看原文]
肿瘤缺氧
为探究肉瘤猫患者队列中缺氧的存在,作为 pH 和代谢的补充标志物,通过两个成熟参数对[18F]FMISO PET 进行定量,即标准摄取值(SUV)和 Patlak 衍生的 Ki。前者通过求和 PET 采集最后 30 分钟获得,提供了类似于临床环境中晚期静态成像的测量。所得 SUV 图像(图5A)显示肿瘤内强烈、异质性摄取;然而,与直接相邻的肌肉组织相比对比度较低。肿瘤亚型之间静态摄取的比较显示 FS 组内存在显著变异(图5B)。其他亚组的静态摄取在组间也差异很大,良性 NF 属于最缺氧的实体。相比之下,UPS 在三个肿瘤的 SUV 上显示高度一致性。肌肉与肿瘤组织之间的低对比度可能由[18F]FMISO 的缓慢洗脱动力学解释。肿瘤和肌肉区域的时间活性曲线表明了这一点(图5C)。此处,两种组织类型的动力学可以清晰区分,但未被成像窗口内的绝对摄取値强烈反映。为将动力学变异印记到图像对比度中,使用图像衍生的动脉输入函数(图5D)对时间活性曲线进行体素级 Patlak 建模。
[图:通过[18F]动力学可视化的肿瘤缺氧]FMISO PET. (A) Exemplary SUV image of a FS G2 summed over the last 30]

所得的参数 Ki 图显示出与静态 SUV 图像位置相似的若干热点;然而,与静态图像相比对比度增加(图 5E)。有趣的是,从 CS、OS、HAS 和 NF 的 SUV 中发现的缺氧差异并未在 Ki 中反映出来(图 5F)。虽然 FS 级别之间的相对差异仍与 SUV 类似,但与 SUV 相比,UPS 组内 Ki 的变异更强。良性 NF 显示出高 SUV,但相对于所有其他亚型仅有中等 Ki。使用哌莫硝唑评估缺氧检测的验证,以中心免疫组化切片上的阳性细胞分数定量。SUV 与哌莫硝唑阳性细胞分数显示出略强但未达显著的相关性(图 S4)。总体而言,所有肿瘤均显示出明显的缺氧,在所有病例中阳性细胞分数均超过 40%。
[内容请查看原文]
肿瘤间异质性
在上述仅针对单一参数的一维亚型比较之后,通过研究两个或更多参数之间可能如何相互关联,可以更好地理解肉瘤中的代谢过程。由于样本量限制,影像生物标志物之间的相关性仅对所有肿瘤和 FS 亚组进行了评估。来自多模态成像方案的四种影像生物标志物(酸化、AUCr、Ki 和 ADC)进行了两两相关性评估。结果总结在涉及所有肿瘤亚型(图 6A)和不同级别 FS 亚型(图 6B)的相关性矩阵中。涉及所有亚型的矩阵显示 AUCr 与 Ki 之间呈强正相关(r = 0.71,p = 0.006),提示丙酮酸向乳酸代谢流是氧可用性低的结果,可能减少了丙酮酸进入 TCA 循环的穿梭。仅在 FS 中也发现类似的相关性,但未达显著(r = 0.50,p = 0.39)。在所有亚型中,AUCr 也与 ADC 呈弱正相关(r = 0.55,p = 0.05),而 FS 中则相反(r = −0.39,p = 0.45),并且由于两个 UPS 实体的 ADC 和 AUCr 特别高,图 1A 显示了相应的示例。另一方面,不同级别的 FS 显示乳酸标记与酸化之间呈强正相关(r = 0.89,p = 0.04),对于绝对 pH 和乳酸产生甚至更为明显(r = −0.97,p = 0.008,未显示)。当考虑所有其他亚型时观察到相同的趋势,但未达到显著性。总体而言,FS 作为亚型组和所有亚型的相关模式相似。除绝对平均值外,还可以使用平均绝对偏差(MAD)比较肿瘤在所检查特征方面的异质性。该值反映了每种模态下肿瘤内所有有效体素的变异,因为不能假定肿瘤异质性遵循高斯分布。在此,pH 异质性遵循与绝对酸化相似的趋势,其中最具侵袭性的肿瘤(FS G3 和 UPSs [47])显示出最高的异质性,亚组内一致性良好,低级别和良性肿瘤异质性低(图 6C)。虽然代谢异质性(AUCr 的 MAD,图 6D)观察到相似的趋势,但 UPSs 之间的变异和良性 NF 中的异质性增加。同样,缺氧异质性(图 6E)似乎也随 FS 级别增加,而 ADC 异质性(图 6F)则未见此现象。值得注意的是,一些亚型似乎仅在单一参数上显示出相对较高的异质性(OS 中的缺氧),而其他亚型则在所有参数上显示出相对较高的异质性(例如 FS G3)。此外,所有参数(酸化、AUCr、Ki 和 ADC)可以组合成 4D 特征坐标。该坐标可以绘制在 3D“代谢空间”中(图 6G),其中 ADC 以颜色编码(CS 无有效 ADC 测量)。对三个空间维度进行主成分分析(PCA)返回一个特征向量,提示缺氧、AUCr 和酸化相互关联,从而支持所提出的功能性肿瘤模型(图 1A)。然而,对于大多数肉瘤,其程度似乎取决于侵袭性,其中 UPSs 偏离此发现最为明显。以类似方式绘制 MADs 时可以观察到相似的模式(图 6H)。虽然不同代谢特征的异质性似乎相互关联,但侵袭性较高的肿瘤,尤其是 FS,出现在该代谢轨迹的上端,提示异质性可能是 FS 中肿瘤侵袭性的潜在标志物。
[图:代谢特征的肿瘤间相关性。所有肿瘤六种成像参数的两两相关矩阵]

[内容请查看原文]
肿瘤内异质性
虽然瘤间相关性有助于了解肉瘤亚型之间的差异,但参数的瘤内相关性可揭示单个肿瘤内或整个群体子集中的代谢关系。为此,在体素水平上对成像参数进行相关性分析,以生成肿瘤特异性相关矩阵。各亚型的示例矩阵概览见图7A。此处,模式显示亚型之间乃至不同级别亚型之间存在巨大差异。然而,应注意的是,与瘤间相关性类似,若干亚型显示pH与AUCr之间存在相关性(图7B I、II),这进一步支持了乳酸驱动酸化机制的假设。在同一UPS中,乳酸代谢与缺氧相关(图7B III)。该分布进一步表明,缺氧区域乳酸标记增加。然而,仅凭此观察并不能确定缺氧是该肿瘤中乳酸增加的原因。有趣的是,一些肿瘤还显示出意料之外的发现。例如,一例FS G2显示ADC与Ki之间呈正相关,这支持了既往发现[48],并与致密肿瘤组织促进缺氧的假设相矛盾(图7B IV)。为进一步深入了解所应用成像模式的代谢依赖性,可将每个肿瘤体素的所有参数绘制为类似于图6G的4D特征坐标。以FS G2为例(图7C),肿瘤体素分布沿3D子空间中的一条轨迹排列,可通过PCA衍生的轨迹(红色)进行可视化。这表明缺氧、随后改变的代谢以及由此产生的细胞外酸化之间存在机制性关系。此外,较高的ADC值似乎与较低的pH、较高的AUCr和增加的Ki相关。为便于跨肿瘤比较,使用所有参数的z分数重复PCA,从而减轻尺度效应并能够直接评估跨肿瘤的参数依赖性。绘制相应的单位向量(类似于图7C),可得到表征每个肿瘤内代谢参数之间关系的“代谢向量”分布(图7D)。弱侵袭性肿瘤(FS G1、NF)显示很小或没有酸化潜力(Δz(pH) ∼ 0或Δz(pH) < 0),而许多侵袭性肿瘤(FS G2、FS G3、UPS)则相反。每个肿瘤依赖无氧糖酵解进行细胞外酸化的程度由PMH评分量化(实验部分“统计与主成分分析”;图7E)。一致地,FS G2、FS G3和UPS作为我们队列中最具侵袭性的肿瘤,与低级别(FS G1)或良性肿瘤(NF)相比表现出最高评分。尽管获取了四种成像生物标志物,累积解释方差图表明大多数肿瘤的异质性仅由两个主成分即可描述,这两个主成分在几乎所有肿瘤中解释了超过80%的方差(图7F)。示例性双标图(图7G;与图7C同一受试者)可视化主成分与测量参数之间的关系,显示源自超极化13C MRSI的pH和AUCr对观察到的异质性贡献最大。从实践角度来看,在仍能全面评估瘤内异质性的同时减少成像模式数量将是有意义的。基于子集的PCA分析确定了两种最能捕捉异质性的模式,在评估每种模式属于描述单一肿瘤实体内大部分异质性的两种模式的频率时,所有四种模式似乎具有相似的重要性(图7H上)。在临床上,如果采集必须限制为一种模式,那么确定单一最具信息量的模式比采用两种成像模式更受关注。基于第二项相应的子集分析,源自[1-13C]丙酮酸超极化13C MRSI的AUCr可被确定为最具信息量的模式(图7H下)。
[图:代谢特征的瘤内相关性。(A) 所有肿瘤类型和级别的代表性相关矩阵]

[内容请查看原文]
患者病例——双形性肿瘤
本研究中的一个特殊病例是发现了一种双形态肿瘤,其在组织病理学上呈现两个形态不同的GP。在该患者中,肿瘤环绕右后肢,在pH图中显示一个酸化热点,与另一个位置偏移的高代谢通量且强[18F]FMISO摄取的热点互补。相比之下,解剖图像和ADC图无定论(图8A)。切除后经H&E组织学评估(图8B左),该肿瘤实体由两个组织形态学上不同的区域组成,具有不同的细胞GP(GP1和GP2)。然而,无论是H&E还是各种应用的免疫组化标记物(“肿瘤形态学”部分)均无法将这些GP明确归入特定的肉瘤亚型。匹莫硝唑染色显示GP2的阳性组织分数略有增加(图8B右),与强PET摄取一致。从组织学向影像模态的配准和ROI转移表明,不同的热点对应于不同的肿瘤区域(图8A插图)。类似于图7A的瘤内相关性分析清楚地将GP1与GP2区域区分开来(图8C)。值得注意的是,GP2区域的矩阵模式与图6B和图7A中FS亚型的总体发现一致。
[图:多模态成像反映双形态肿瘤的肿瘤区域化。(A)与解剖图像相比,参数]

此外,两个区域显示出明显可区分的“糖酵解向量”,这表明通过多模态成像对区域进行无创区分的可能性(图8D)。为评估基于所应用影像模态对两个区域的可区分性,生成了所有已分配区域体素的直方图(图8E)。在此,pH可清晰分离两个区域(p < 0.0001),而代谢也能可靠区分两个区域(p = 0.006)。相比之下,PET参数,即Ki和SUV,以及ADC,未能区分体素群体,提示超极化13C MRSI在表征瘤内和瘤间代谢异质性方面具有高价值。
[内容请查看原文]
多模态成像的预后潜力
通过研究开始后长达四年的随访调查评估了每种影像生物标志物评估患者结局的能力(图S5)。更强的缺氧,由SUV升高(图9A)或Ki值升高(图9B)指示,指向中位生存期缩短,但尚无定论。有趣的是,较高的ADC值似乎与中位生存期缩短超过四倍相关(图9C),但未达到显著性。超极化13C MRSI同样如此,其中丙酮酸向乳酸转化的较高代谢通量(图9D)显示出中位生存期强烈缩短的趋势。
[图:使用影像参数的Kaplan–Meier生存分析。静态(A)和动态(B)参数二分组的生存曲线]

对于pH成像,pH归一化很重要,因为绝对pH(图9E)无法清晰区分患者组。相比之下,超过0.1个pH单位的酸化被建议作为合适的截断值,因为它可区分中位生存期缩短3.8倍(图9F),因此是我们小型队列研究中最相关的预后影像参数。如组二分法所示,缺氧增加、ADC较高、代谢活性高和强酸化是不利的肿瘤特征。这也反映在总生存时间与相应参数的直接相关性分析中(图S6)。在此情况下,酸化、代谢和ADC与总生存期的相关性最强,酸化最强的肿瘤导致最短的生存时间。此外,为评估潜在混杂因素,评估了表S1中的元参数肿瘤体积、年龄、体重、性别、品种和肿瘤位置的预测潜力(图S7A–F)。在我们的队列中,这些因素似乎均与预测猫的结局无关。连续元参数年龄、体重和肿瘤体积的相关性表明,年龄与SUV和体积呈负相关,而体积与ADC和AUCr呈正相关(图S7G)。分类元参数对影像参数无相关混杂影响(图S7H),但有趣的是,位于腹壁的肿瘤与位于身体其他部位的肿瘤(平均ΔpH = 0.19,图S7H)相比,酸化显著较低(平均ΔpH = 0.05)。
[内容请查看原文]
讨论
本研究旨在建立一套临床相关的工作流程,在3 T临床PET/MRI系统上同时评估细胞外pH、代谢和缺氧状态,采用高极化13C MRSI进行pH测定,并结合高极化[1‐13C]丙酮酸MRSI和[18F]FMISO PET,在自发性猫肿瘤中实施。新型MRI技术临床转化的挑战之一是从临床前扫描仪(大多在7 T及以上场强运行)过渡到临床3 T系统。在3 T下,频谱分辨率较低,这使频谱归属变得复杂,尤其是pH评估。然而,与7 T相比,3 T下丙酮酸和zymonic酸的13C T1弛豫时间常数延长[44],这使得高极化磁化强度的可用时间更长,从而获得更好的信噪比。本研究基于全面的猫患者数据,证明了技术可行性,特别是高极化方案向临床环境的缩放,以及可靠的测量准确性。这清楚表明,使用[1,5‐13C2,3,6,6,6‐D4]zymonic酸等探针进行基于化学位移的pH成像,在临床环境中可产生稳健的空间分辨读数。总之,这些发现支持了以下前提:高极化13C pH成像不仅技术上可行,而且对进一步转化开发具有价值。
尽管血细胞计数和动物监测表明本研究中注射和成像程序耐受性良好,但专门毒理学研究和无菌配制工作流程的开发对于[1,5‐13C2,3,6,6,6‐D4]zymonic酸的临床转化至关重要。相比之下,[1‐13C]丙酮酸已在临床试验中使用[20],而[18F]FMISO已在某些中心的临床实践中确立,这降低了所提出联合方案未来在人体中实施的障碍[19]。
同时、配准映射缺氧、代谢和细胞外pH的一个关键动机是肿瘤异质性,因为这些参数在病变内可能差异很大,而序贯测量使空间对应和机制解释复杂化。本研究中,自发性猫肿瘤作为啮齿动物和人类之间的中间模型,因为它们表现出与人类肿瘤相似的形态学特征,且在大小和基础代谢率上更接近人类对应物,这突显了宠物自发性肿瘤在比较生物医学研究中的潜力和适用性[49]。本研究队列中观察到的高的瘤间和瘤内变异性强调了这一点。同时,队列规模适中且每种组织学亚型数量有限,需要谨慎解释,特别是对于亚型特异性生物学机制的论断。
有趣的是,DWI在整个研究队列中产生了相对较高的ADC值(1.79–2.91 ∙ 10−3 mm2/s)。先前在良性和恶性软组织肿瘤(包括肉瘤)中也发现了类似的高值[50]。然而,恶性病变通常观察到较低的值(0.87–1.40 ∙ 10−3 mm2/s)[51],特别是软组织肉瘤(0.47–2.09 ∙ 10−3 mm2/s)[52, 53, 54],后者由于细胞密度、细胞外基质组成、坏死和水肿的不同而具有强异质性。pH和代谢成像指出了本研究所调查亚型之间的潜在差异。使用13C标记的氘代zymonic酸作为探针的pH成像首次在猫中展示。虽然本研究的pH测量未通过血气分析等金标准或31P MRSI或CEST等其他成像读数验证,但zymonic酸作为pH传感器已在先前研究中针对其他技术进行了仔细验证[22]。本工作中的pH成像揭示了肿瘤中明显的酸化热点以及几种亚型的整体肿瘤酸化。然而,本研究报告的平均pH值包含来自非酸化血管腔室的权重,这解释了为何本研究中发现的绝对pH值相比先前肉瘤pH研究[55, 56, 57]显得酸化程度较低。观察到的肿瘤酸化与先前犬肉瘤患者的研究结果一致,其中肿瘤酸化被认为是侵袭性和预后不良的指标[58]。虽然UPS通常被认为高度侵袭性[47],但OS和CS已被认为通过增加CAIX和vATPase表达来酸化其细胞外空间[46]。这与本研究OS病例中观察到的强酸化和低代谢通量相符。这一观察支持了直接测量pH而非仅从代谢推断的理由。
本研究中用于量化代谢的AUCr值也表明,在大多数肉瘤病例中,丙酮酸向乳酸转化存在强烈的代谢通量,尽管肿瘤之间及病灶内部存在显著异质性。鉴于时间分辨率较低且含信号的数据点数量有限,基于AUCr的量化方法为本次采集提供了一种实用的汇总指标。然而,通过对动态成像数据进行动力学建模[59]以及以更高空间和时间分辨率进行采集[60, 61],可能降低变异性。即使存在这些局限性,观察到的乳酸生成与肉瘤代谢重编程的更广泛概念相一致[62]。一个原因可能是,尽管对葡萄糖和氧气消耗的需求增加,但研究发现肉瘤中葡萄糖氧化受损[63]。
[18F]FMISO的PET成像可以很好地整合到超极化13C MRSI工作流程中,从而在成像会话内实现额外的乏氧成像。动脉输入函数定量因在PET采集期间插入双调谐MRI线圈而受到影响,这引起了进一步的衰减。然而,动力学建模和晚期时间点的静态平均均未受到这一技术负担的显著影响,因为线圈插入发生在输入函数峰值之后,且在用于建模的肿瘤时间-活性曲线段之前。与健康组织相比,SUV和Ki值升高提示乏氧,并得到哌莫硝唑染色的证实,这与先前在猫肉瘤患者中基于PET的乏氧成像研究一致[64, 65]。出乎意料的是,哌莫硝唑分析与PET参数之间的相关性仍然有限,可能是由于不同的标度和层厚所致——这与将PET乏氧示踪剂与离体乏氧标志物定量关联的已知挑战相一致[66]。虽然SUV与哌莫硝唑的相关性略强于Ki,但已证明这些参数在预后和治疗结局方面无差异[67]。与我们的结果相似,纳入肉瘤患者进行[18F]FMISO PET的临床研究提示肉瘤侵袭性与乏氧之间存在关联,但相关证据仍处于早期阶段[65, 68]。
虽然在本研究中PET乏氧生物标志物作为患者结局预测因素尚无定论,但肿瘤内异质性最好通过使用[1‐13C]丙酮酸的代谢成像来捕捉。通过使用[1,5‐13C2,3,6,6,6‐D4]zymonic酸进行超极化13C MRSI测量pH所评估的肿瘤酸化,在所有研究的参数中被证明是患者结局的有前景的预测生物标志物。这与临床动机相一致,即假设细胞外酸度塑造抗肿瘤免疫,并可能代表一种可改变的脆弱性。如果在更大规模的研究中得到证实,pH成像可以补充乏氧和代谢读数,用于分层和治疗监测,并有助于识别最有可能从微环境靶向调理策略中获益的肿瘤。
本研究的一个主要局限性是每种亚型的患者数量较少,其中几种亚型仅包括一个患者病例。此外,正如双形性肿瘤所示,即使在综合组织病理学检查下,兽医患者中的亚型分化也并不总是可行的。这里的一个主要挑战是,与人类诊断相比,猫物种特异性免疫组化标志物的可用性有限。这限制了基于影像进一步表征区室亚型的能力。此外,收集所有具有足够质量以进行多参数分析的数据具有挑战性,需要初步经验和优化。这进一步限制了完整数据集的数量。
在此项工作之前,已有研究将超极化13C MRSI与PET联合使用。这些研究发现乳酸生成与[18F]FDG之间存在相关性[30],并进一步能够区分犬癌症患者的骨肉瘤与软组织肉瘤[31]。在这些研究中,还观察到不同亚型之间主要参数k pl与FDG摄取相关性的差异。然而,未发现跨不同肿瘤的普遍模式,这证实了肉瘤的高度多样性和代谢复杂性。在大鼠研究中也发现了类似结果[27],其中细胞密度和坏死被认为是重要的潜在混杂因素。此外,多种模态的联合可能在更好地评估早期治疗反应方面更为可靠[69]。除了有时被认为相互竞争的超极化[1‐13C]丙酮酸和[18F]FDG[70]之外,在多模态环境中真正互补的成像已被用于评估代谢与血管化或受体表达的关系[32, 33]。此外,特别是PET/MRI已被证明在理解复杂疾病和利用多模态成像多功能性方面具有重要价值,例如在阿尔茨海默病中结合PET与功能性MRI[71, 72, 73]。过去几十年成像硬件的发展催生了多种强大的多模态设备。这些设备跨越不同尺度,从单细胞水平的体外平台[74]到人类的临床常规应用[75]。PET与MRI分子成像有时被认为是疾病诊断和治疗决策主导权上的对手。相反,越来越清楚的是,利用其互补性的多模态方法为诊断和治疗反应评估提供了额外价值。
[内容请查看原文]
结论
总之,本工作通过在3 T PET/MRI系统上实施单次会话、临床现实可行的方案,同时测量缺氧([18F]FMISO)、代谢通量(超极化[1‐13C]丙酮酸)和细胞外pH(超极化[1,5‐13C2,3,6,6,6‐D4]zymonic acid),推进了转化多模态成像。猫肉瘤通过能够在临床工作流程环境中评估可行性、共定位和异质性,为啮齿动物研究与人类应用之间提供了实用的桥梁。值得注意的是,pH映射被证明对表征瘤内和瘤间异质性及预测患者结局具有价值。如果在更大队列中得到验证,该方法可支持用于分层和治疗监测的生物标志物开发。
[内容请查看原文]
实验部分
[内容请查看原文]
研究设计与工作流程
本研究评估了同时进行超极化13C MRSI和PET的可行性与耐受性,以直接对比研究缺氧、代谢和肿瘤酸化。实验按照相关法律法规进行,并获得伦理审查委员会批准(Regierung von Oberbayern,ROB‐55.2‐2532.Vet_02‐17‐177)。患者通过发送至德国巴伐利亚大量兽医诊所的通讯招募。表达研究兴趣并提供书面知情同意、且具有可触及肿块的宠物猫接受了活检、血细胞计数、心肺检查和超声检查。纳入标准为确诊的、可根治性切除的、触诊直径至少2 cm的恶性间叶性肿块。复发或转移性肿瘤为排除标准。在多模态成像方案之前,从主人处收集了关于研究风险和条件的书面知情同意。所有纳入患者的年龄、性别、品种和体重列于表S1。在成像前和成像后直接进行血细胞计数,以评估即时不良副作用。在成像期间,动物由至少一名经验丰富的兽医全程称重、处理和持续监测。为注射成像剂,在一侧前肢放置导管。通过静脉注射丙泊酚诱导麻醉。猫被插管,麻醉通过使用异氟烷(0.8%–2.8%)以富氧(40%)医用空气为载体气体的控制通气维持。通过向孔内吹入暖空气维持体温(Mistral air,The 37C Company,Amersfoort,Netherlands)。使用MR兼容温度监测系统Model 1030(SA Instruments,Stony Brook,USA)监测直肠温度。使用MR兼容患者监护仪(Expression MR Patient Monitor,Invivo,Gainesville,USA)监测心率和外周血氧饱和度(SpO2)。此外,持续监测呼气末CO2(EtCO2)、吸气峰压和呼吸分钟通气量。成像和患者苏醒后,根据辐射防护规定将猫归还给主人。为手术规划,解剖MR图像由经验丰富的临床人类放射科医生和兽医放射科医生诊断。所有猫均接受肿瘤切除手术,通常在成像后3–5天,并在随访期内未接受进一步肿瘤相关治疗。切除的肿瘤标本进行组织病理学评估以确认肿瘤完全切除(R0状态)。组织病理学处理后,所有切除肿瘤由经验丰富的病理学家进行显微镜评估。肿瘤类型、位置、范围和体积的完整列表提供于表S1。
[内容请查看原文]
超极化
对于pH成像,将213.4 mg [1,5‐13C2,3,6,6,6‐D4]zymonic acid(内部合成)[44]与8.5 mg OX063三苯甲基自由基(GE Healthcare,Chicago,USA)混合,并加入190 µl二甲基亚砜。混合物涡旋90分钟,转移至DNP样品杯,并在液氮中冷冻。对于与[13C]尿素的共极化,加入135 µL含30 mm OX063的10 m [13C]尿素甘油溶液,样品杯再次在液氮中冷冻。然后样品在HyperSense DNP极化仪(Oxford Instruments,Abingdon,UK)中通过DNP极化,微波频率94.190 GHz,功率100 mW,至少3–4小时。达到饱和极化后,使用加热至180°C的9 mL溶解剂进行溶解。溶解剂由7.65 mL含80 mm三羟甲基氨基甲烷(TRIS)和0.1 g/L Na2-乙二胺四乙酸(EDTA)的D2O组成,并加入1.35 mL 1 m NaOH的D2O溶液。所得注射溶液含有150 mm zymonic acid和150 mm尿素,pH为8.08 ± 1.78。对于代谢成像,将96 µL含14 m [1‐13C]丙酮酸(Sigma–Aldrich,St. Louis,USA)、15 mm OX063和1 mm DOTAREM(Guerbet,Villepinte,France)的溶液加入DNP样品杯,并在HyperSense DNP极化仪中以微波频率94.190 GHz和100 mW功率极化至少30分钟。样品使用8.307 mL含80 mm TRIS和0.1 g/L Na2EDTA的H2O缓冲液与0.693 mL 1 m NaOH的H2O溶液的混合物溶解。所得注射溶液含有150 mm丙酮酸,pH为6.06 ± 1.73。
[内容请查看原文]
成像方案
成像在临床3 T PET/MRI扫描仪(Biograph mMR,Siemens Healthcare,Erlangen,Germany)上使用syngo VE11P服务包3进行。麻醉诱导后,将猫以肿瘤朝下的方式居中放置在安装于临床扫描仪患者床上的内部制作床上。初始定位扫描、衰减图和全身3D成像(实验部分“解剖MRI”)使用扫描仪体线圈采集。对于后续13C MRSI(实验部分“13C MRSI”),将横截面为21 cm × 32 cm的双调谐柔性1H/13C Tx/Rx表面线圈(Rapid Biomedical,Rimpar,Germany)插入猫床导轨系统,以将线圈直接置于肿瘤下方而不移动猫。
[内容请查看原文]
解剖MRI
使用标准定位序列验证初始患者体位。与PET采集开始同步,采用基于标准广义自动校准部分并行采集(GRAPPA)的3D快速小角度激发(FLASH)双回波Dixon序列[76, 77, 78]进行基于脂肪-水的衰减映射,矩阵126 × 192 × 128,分辨率2.64 × 2.64 × 3.12 mm³,TR 3.56 ms,TE 1.23 ms,总采集时间31.34 s。用于原发肿瘤定位和潜在额外病灶检测的全身3D成像采用3D磁化准备快速梯度回波(MPRAGE)序列,典型参数为矩阵120 × 320 × 192,分辨率0.5 × 0.5 × 1 mm³,TR 2050 ms,反转时间(TI)1040 ms,TE 4.16 ms,4次平均,总采集时间8 min 11 s。第二个3D序列,即3D流体衰减反转恢复(FLAIR)序列,以典型参数采集:矩阵144 × 384 × 192,分辨率0.83 × 0.83 × 1 mm³,TR 3000 ms,TI 1800 ms,TE 393 ms,回波链长度258,4次平均,总采集时间8 min 21 s。此外,为MRSI层面定位,采集轴位、矢状位和冠状位2D FLASH T1加权图像,典型参数为矩阵216 × 384 × 35,层厚3 mm,分辨率0.41 × 0.41 × 3 mm³,TR 250 ms,TE 2.84 ms,12次平均,总采集时间4 min 47 s。为MRSI层面的解剖学配准,采集使用半傅里叶采集单次激发涡轮自旋回波成像(HASTE)的T2加权图像,矩阵144 × 384 × 3,层厚3 mm,分辨率0.41 × 0.41 × 3 mm³,层间距4.98 mm,TR 2000 ms,TE 49 ms,32次平均,总采集时间3 min 6 s。
[内容请查看原文]
13C MRSI
使用常规用户交互式图谱匀场工具进行匀场,并使用掺杂Gd-DOTA的8 M [13C]尿素体模校准13C频率。通过搜索在尿素体模单次13C谱中返回最高13C信号的参考电压来手动调整线圈参考电压。对于pH的超极化成像,猫注射8 mL超极化zymonic acid-尿素溶液,注射在溶解后38 ± 3 s开始,注射持续时间14 ± 2 s。pH成像的自由感应衰减化学位移成像(FIDCSI)在注射结束时开始,采用15°翻转角,矩阵8 × 16,椭圆k空间编码,FOV 80 × 160 mm²,层厚13 mm,平面内分辨率10 × 10 mm²,TR 156 ms,光谱接收带宽4000 Hz,256个光谱点,采集时间10.14 s作为典型参数。对于丙酮酸-乳酸标记交换的超极化成像,在zymonic acid注射后55 ± 11 min延迟时,于溶解后38 ± 6 s注射8 mL超极化丙酮酸溶液,注射持续时间14 ± 3 s。动态CSI使用与pH超极化成像相同的参数,但总共采集2 × 8帧,总体16帧,典型时间分辨率为10.14 s,总采集时间162.24 s。采集在注射开始时启动。
[内容请查看原文]
弥散加权成像
DWI使用标准2D回波平面成像(EPI)序列“ep2d”,典型参数为:矩阵60 × 128 × 3,层厚3 mm,分辨率1.5 × 1.5 × 3 mm³,层间距4.98 mm,TR 3000 ms,TE 49 ms,4次平均,总采集时间7 min 36 s。对于弥散编码,采集8个b值(0、50、100、200、300、500、800、1000 s/mm²)图像,后两者进行8次平均。b值图像采用带偏移的单指数模型逐体素拟合以得出ADC值。信号强度低于中位数两倍且ADC拟合不收敛(范围0–5·10⁻³ mm²/s)的体素被剔除。
[内容请查看原文]
PET成像
对于PET成像,PET数据以大型列表模式文件采集,总计180 min。由于文件大小限制,PET采集分为第一段持续60 min和第二段持续120 min。采集在注射溶于2 mL无柠檬酸盐溶液(ABX,Radeberg,德国)的149.7 ± 7.6 MBq [18F]FMISO之前立即开始。两段的PET图像分别使用GRAPPA衰减图和以下分帧重建:第一段为20 × 3 s、12 × 5 s、26 × 30 s、3 × 300 s、3 × 600 s,第二段分帧为12 × 600 s。两段的医学数字成像和通信(DICOM)图像使用内部编写的Python脚本合并为一个联合序列。
[内容请查看原文]
组织病理学
手术前1小时,给猫注射0.3 g/m2哌莫硝唑(Hypoxyprobe Inc.,美国伯灵顿),用于免疫组化显示缺氧情况。手术后,用不同颜色的组织墨水标记肿瘤以编码绝对方向,并在福尔马林中适当固定(组织与福尔马林比例为1:10)。为了与影像数据进行配准,根据13C MRSI切片方向将肿瘤切成0.5 cm厚的切片,并将每个切片切成更小的块以装入组织学 cassette(41 mm × 27.5 mm × 12 mm,Carl Roth,#EE16.1)。然后按照标准方案对肿瘤进行H&E染色。使用异硫氰酸荧光素(FITC)标记的抗哌莫硝唑抗体(Hypoxyprobe Inc.,#HP2-1000Kit,一抗:批号05.18.18,二抗:批号08.23.18),随后使用辣根过氧化物酶(HRP)偶联的抗FITC二抗,以免疫组化方式显示并确认[18F]FMISO PET检测到的组织缺氧。未接受哌莫硝唑注射的猫患者的猫纤维肉瘤常规诊断样本用作阴性对照(图S3)。基于H&E组织形态学以及(如适用)免疫组化标记物特征,然后根据现行兽医WHO分类和兽医病理学标准对肿瘤进行分类[45,79,80]。此外,根据猫纤维肉瘤分级指南对纤维肉瘤进行分级(G1=低级别,G2=中级别,G3=高级别)[40]。
[内容请查看原文]
血细胞计数
对于每位患者,至少采集两份血液样本(一份在成像前,一份在成像后),最多采集四份血液样本,装入S-Monovette EDTA K3E(Sarstedt,德国Sarstedt)。使用Sysmex XT-2000iVet(Sysmex,日本神户)进行血细胞计数。使用Roche Cobas Integra 400 plus(Roche,瑞士巴塞尔)分析血清。
[内容请查看原文]
随访调查
为了评估手术切除肿瘤后患者的结局,进行了随访调查,询问与所诊断肿瘤相关的后续治疗、复发和生存状态。为此,在2024年7月至2024年9月期间通过电话联系了猫患者主人。调查表见图S5。该调查由九位猫患者主人完成,一位患者的总体生存信息从临床兽医医学中心的随访访视中获得。对于生存分析,将具有随访信息的患者分为预后良好组和预后不良组。为了确定最佳参数特异性截断值,对三个不同时间点(6、12、18个月)进行了ROC曲线分析,并通过计算Youden指数为每条ROC曲线选择最佳截断值。然后将得出的截断值在所有三个时间点上取平均值,得到最终截断值。显著性通过p值≤0.05确定,使用Mantel-Cox检验进行检验。
[内容请查看原文]
数据分析
MATLAB(The MathWorks,美国纳蒂克)中脚本的生成由大型语言模型(ChatGPT,OpenAI,美国旧金山)协助完成。由于本初步研究的探索性性质,在任何阶段均未采用盲法。为了对所有成像模态进行配准,将DWI和PET图像及相关参数图降采样,以匹配四倍插值13C采集的分辨率。
[内容请查看原文]
pH图重建
为了重建pH图,通过TWIX导出原始数据文件。所有后处理均在MATLAB 2022b中使用类似于先前描述的图形用户界面(GUI)平台进行[23]。具体而言,CSI原始数据在光谱维度上零填充2倍,在空间方向上插值4倍,并进行6 Hz线增宽。对于pH拟合,搜索[13C]尿素和最多四个zymonic acid峰(C1和C5)。后者对应两个区室,根据先前研究结果,区室范围分别为7.25–7.9和6.6–7.25[22,23],相对于切趾光谱边缘的最低信噪比(SNR)为20。使用已报道的校准曲线,根据相对于尿素的峰位置拟合pH值[22]。对于包含一个以上pH区室的体素,以峰强度为权重对平均pH值进行加权平均,本研究中仅报告为pH。肿瘤平均pH值在整个肿瘤ROI内取平均值。酸化ΔpH定义为同一受试者相邻肌肉区域pH(pHmuscle)减去肿瘤pH(pHtumor),仅用于肿瘤间比较:ΔpH=pHmuscle−pHtumor
[内容请查看原文]
丙酮酸-乳酸标记交换的定量
为了定量丙酮酸-乳酸标记交换,通过TWIX导出原始数据文件。所有后处理均在MATLAB 2022b中使用类似于先前描述的GUI平台进行[23]。具体而言,CSI原始数据在光谱维度上零填充2倍,在空间方向上插值4倍,并进行6 Hz线增宽。[1-13C]丙酮酸和[1-13C]乳酸峰位置在16 Hz范围内积分,所得时间曲线进行基线校正。然后将丙酮酸和乳酸时间曲线随时间求和,并将累积乳酸信号除以累积丙酮酸信号以获得AUCr值。丙酮酸峰SNR低于5的体素被排除。
[内容请查看原文]
缺氧的定量
PET数据的定量和后处理使用Inveon Research Workplace 4.2(Siemens Healthineers,埃尔朗根,德国)完成。导入PET图像、解剖3D和2D MRSI体积匹配MR图像,并在必要时使用刚性旋转或平移手动微调配准。将PET信号强度转换为SUV,并对最后30分钟(对应三帧)的强度值取平均值。由此得出静态晚期摄取值为缺氧的衡量指标,正如临床研究中常用的那样[81]。作为量化缺氧的第二种方法,对显示线性摄取动力学的晚期摄取阶段使用Patlak模型进行建模[82]。对于药代动力学建模,在靠近肿瘤位置的腔静脉段上绘制感兴趣区,提取的时间曲线作为图像衍生的输入函数用于建模。使用该输入函数和从t=60分钟到t=180分钟(第二采集区块)的动态曲线进行体素级动力学建模,生成动力学摄取率(Ki)图,其中正值表示缺氧程度增加[66]。
[内容请查看原文]
免疫组化染色的定量
扫描的玻片在QuPath 0.5.1中分析[83]。首先,通过使用强阳性和阴性切片区域分别对每张玻片的二氨基联苯胺和苏木精染色向量进行调整,实现颜色解卷积。缺氧阳性细胞分数的计算使用内置的阳性细胞检测算法和二元阈值完成。二元阈值通过阳性和阴性对照切片的对照分类确定。每种免疫组化染色的检测和分类参数列于图S4G中。
[内容请查看原文]
统计与主成分分析
统计分析使用GraphPad Prism 7(GraphPad Software,圣地亚哥,美国)进行,根据数据集是否呈正态分布使用双侧t检验或Mann–Whitney U检验。双参数线性回归分析在Origin 2018b(OriginLab,北安普顿,美国)中进行。p ≤ 0.05的值被认为具有统计学显著性。对于肿瘤间相关矩阵,将全肿瘤平均参数值或个体体素参数成对绘制并使用线性回归拟合。对于瘤内相关分析,ADC值在所有三个成像切片上逐体素求和,PET和DWI参数图重采样以匹配插值13C参数图的分辨率。对于参数关系的多维分析,使用MATLAB内置算法对具有完整有效成像数据集的对象的三项参数(pH/Ac.、AUCr、SUV)或四项参数(pH/Ac.、AUCr、SUV、ADC)进行PCA。对于一般参数依赖性的定性可视化,使用非标准化参数,并显示第一特征向量轴(如图7C所示)。对于定量分析(图7D–H),使用所有肿瘤的全局中位数和四分位距计算每个参数的z分数[84, 85]。为了评估肿瘤内缺氧驱动的乳酸代谢程度及相关的细胞外酸中毒,将“pH-代谢-缺氧(PMH)评分”定义为第一PCA向量与归一化“Warburg向量”W = [-1, 1, 1]/3之间点积的绝对值。
[内容请查看原文]
基于子集的瘤内异质性PCA分析
为了确定捕获肿瘤异质性的两个或单个最具信息量的成像模态,采用了一种受主变量概念启发的基于投影的子集评估方法[86, 87, 88]。为了确定单个最具描述性的模态,对每个肿瘤的每个参数(pH、AUCr、Ki、ADC)分别评估其保留由肿瘤内全参数集PCA定义的主导多变量异质性模式的能力。为此,通过将每个肿瘤的体素数据划分为五个大致相等的子集进行5折交叉验证。在每次迭代中,使用其中四个部分Sfit对所含PCA得分Sfit和所测试模态的z分数进行带偏移的线性最小二乘回归,剩余子集Stest留作测试。
然后将拟合的回归系数应用于留出的测试子集以预测相应的PCA得分S^test。预测准确性使用决定系数量化:R2=1−SSESST,其中SSE=∑Stest−S^test2是测试子集中真实与预测PCA得分之间的残差平方和,SST=∑Stest−S¯fit2是相对于用于拟合的子集平均PCA得分的总平方和。该过程重复五次,使每个子集各作为一次测试数据,所得R2值取平均。平均R2最高的模态被认为最能保留肿瘤由PCA定义的主导异质性结构。为了确定两个最具描述性的模态,应用与单模态相同的工作流程,但使用两个模态的z分数进行线性回归。对所有参数对重复该分析,最佳参数对由肿瘤内所有参数对中R2的最大值确定。
作者贡献
概念化:MS、KS、AML、JH、CB、FS。方法学:MG、TG、SB、JC、MS、KS、AML、JH、FS。研究实施:MG、TG、SK、SB、EB、FHAvH、PW。形式分析:MG、TG、AW、JC、SN、CL、KS、FS。可视化:MG、TG、FS。资金获取:MS、WW、KS、AML、JH、CB、FS。项目管理:WW、KS、AML、JH、CB、FS。监督:JH、FS。写作——初稿:MG、TG、FS。写作——审阅与编辑:MG、TG、AW、PW、FS。
资金
本研究由德国研究基金会(DFG,German Research Foundation,Sonderforschungsbereich(SFB)824,子项目A7、Z2和Z3,Emmy Noether项目资助编号391523415(MS、WW、KS、FS)资助。巴伐利亚科学与人文学院青年学院(FS)。欧盟“地平线2020”研究与创新计划,资助协议编号820374(FS)。德国联邦研究、技术和空间部(BMFTR)在“量子技术——从基础研究到市场”资助计划下的“QuE‐MRT”项目,合同编号:13N16450(FS)。
利益冲突
FS在NVision Imaging Technologies GmbH的科学顾问委员会任职。
支持信息
[内容请查看原文]
查看英文原文▾
ABSTRACT
Direct in vivo characterization of the interplay between tumor hypoxia, acidosis, and metabolic reprogramming remains a major translational challenge. Here, we establish a clinically deployable simultaneous PET/MRI workflow on a clinical 3 T system that combines hyperpolarized 13C MRI of [1‐13C]pyruvate to map metabolic flux, [1,5‐13C2,3,6,6,6‐D4]zymonic acid to probe extracellular pH, and [18F]FMISO PET to quantify hypoxia. Recruitment of domestic cats bearing sarcoma as a clinically relevant and comparative disease model yielded a highly heterogeneous study cohort. All modalities could be applied successfully and allow for simultaneous, coregistered mapping of acidification in spontaneous tumors in domestic cats for the first time, complemented by imaging of metabolism and hypoxia. Correlation of imaging parameters provides a multi‐dimensional assessment of inter‐ and intratumoral heterogeneity, which indicates distinct parameter correlation fingerprints for different subtypes. This multiparametric protocol allows for new insights into the metabolic program of sarcoma, suggesting tumor acidification to be coupled with hypoxia and increased lactate production. Moreover, pH imaging shows strong potential for assessing sarcoma aggressiveness and related subject outcomes. Together, these results establish a translationally deployable, simultaneous PET/MRI workflow for integrated imaging of tumor metabolism and microenvironment, which supports efforts to translate pH imaging for patient stratification and therapy monitoring.
[内容请查看原文]
Introduction
Cancer cells often increase lactate production, as deregulation of metabolism is a hallmark of cancers [1]. Otto Warburg recognized early on that enhanced glycolysis and lactate formation can occur even in the presence of oxygen [2], yet hypoxia signaling acts manifold on metabolic pathways [3]. Lactate export can contribute to acidification of the extracellular space [4], which can be further exacerbated by multiple other mechanisms. Tumor acidity has been linked to proliferation, metastasis, and immune escape [5, 6, 7, 8]. Clinically, acidity is relevant because it shapes antitumor immunity [7] and may represent a modifiable vulnerability through microenvironment‐targeted conditioning strategies [9]. Together, hypoxia, lactate‐associated metabolism, and extracellular pH constitute key, interrelated parameters in tumor biology [10]. They are frequently treated as tightly coupled hallmarks of solid tumors, and several imaging studies have assessed pairs [11, 12, 13, 14, 15, 16, 17, 18] of these factors. However, a clinically transferable, simultaneous protocol that measures all three within the same imaging session has, to our knowledge, not yet been established.
Hybrid PET/MRI provides a translational platform to combine established hypoxia tracers such as [18F]Fluoromisonidazole ([18F]FMISO) [19] with emerging molecular magnetic resonance imaging (MRI) methods. Hyperpolarized 13C MRI is a novel technique that has been translated into human studies [20], enables radiation‐free, non‐invasive assessment of metabolic flux [21], and has also enabled pH‐sensitive readouts using suitable probes [22, 23, 24, 25]. Integration of positron emission tomography (PET) with hyperpolarized 13C MRI has been demonstrated in preclinical small [26, 27, 28] and large animal studies [29, 30, 31, 32], and early clinical studies are emerging [33, 34]. To date, however, most combined PET–hyperpolarized 13C studies have focused on complementary assessment of tumor metabolism using hyperpolarized [1‐13C]pyruvate together with [18F]FDG PET, without directly addressing hypoxia or pH.
A method for robust, non‐invasive pH imaging is an unmet clinical need. Despite substantial efforts to characterize acidic tumor regions, a method to measure tissue extracellular pH is not routinely available in clinical practice and research, limiting testing of acidification models and the evaluation of pH as a biomarker for stratification or therapy monitoring [24, 35, 36, 37]. In addition, tumor heterogeneity renders imaging of the tumor microenvironment highly relevant: hypoxia, metabolism, and acidity can vary markedly within the same lesion, and sequential or separate measurements complicate co‐localization and interpretation.
Comparative oncology in domestic cats offers a particularly interesting path toward translation. Cats have basal metabolic rates closer to those of humans (approximately 2.5‐fold higher than the human rate, compared with ∼ 10‐fold higher in mice) [38, 39], and spontaneously arising feline sarcomas provide an abundant, clinically managed tumor model. These tumors arise in skin and connective tissues and are often linked historically to formerly used vaccines and their adjuvants (feline injection site sarcomas) [40]. Mesenchymal tumors are among the most frequent feline cancers and exhibit a high proportion of malignancy in a retrospective epidemiology study spanning over four decades [41]. Importantly, feline sarcomas share metabolic characteristics reported in human sarcoma, including increased glucose utilization and elevated pyruvate‐to‐lactate conversion [42]. This metabolic rewiring is often independent of hypoxia [2, 43], which itself is often present in solid, dense tumors with high cellularity. Subsequent extravasation of lactate can then cause acidification of the extracellular space, thereby promoting immune escape and proliferation (Figure 1A).
[图:Study workflow to image key features of the tumor microenvironment—metabolism, hypoxia, pH, and cellularity. (A) Tumor c]

Within this work, we implement and evaluate a simultaneous imaging protocol on a clinical 3 T PET/MRI system that combines hyperpolarized 13C magnetic resonance spectroscopic imaging (MRSI) of pH using [1,5‐13C2,3,6,6,6‐D4]zymonic acid [22, 44], hyperpolarized 13C MRSI using [1‐13C]pyruvate to probe metabolism, and PET‐based hypoxia imaging using [18F]FMISO in feline sarcoma patients. We report the feasibility of a combined imaging approach that, for the first time, implements spatially resolved pH mapping in spontaneous sarcoma alongside coregistration with hypoxia and metabolic flux maps. We further explore spatial heterogeneity in these parameters both across tumors and within individual tumors. The presented protocol integrates the assessment of three frequently invoked tumor hallmarks in a clinically relevant setting, thereby supporting the mechanistic evaluation of the relation between hypoxia, metabolism, and pH and to inform translational development of pH‐sensitive imaging biomarkers for diagnosis, stratification, and therapy monitoring.
[内容请查看原文]
Results
[内容请查看原文]
Tumor Morphology
In total, 17 patients (Table S1) with biopsy‐confirmed malignant mesenchymal neoplasms and one benign neurofibroma patient were included in the study and underwent the full imaging protocol, consisting of hyperpolarized 13C MRSI, PET, and anatomical imaging (Figure 1B,C). All monitoring parameters acquired during the imaging session show no adverse trends and indicate that all cats tolerated the injections and anesthesia well (Figure S1). Relative comparison of pre‐ and post‐imaging blood counts and serum analysis, as well as comparison to reference ranges, shows no relevant adverse hematologic effects due to the imaging‐related protocol and injections (Figure S2). All lesions manifested as identifiable but not always clearly delimitable in both T 1‐ and T 2‐weighted images. No additional secondary lesions or metastasis were observable by MRI. Several tumors showed anatomical heterogeneity consisting of areas of solid tumor tissue and areas of tissue‐loss (cysts, necrosis), including free fluid. Accordingly, diffusion‐weighted imaging (DWI) revealed regions of high and moderately low apparent diffusion coefficient (ADC) values for fluid‐containing and solid tissue areas, respectively (Figure 2A). Whole‐tumor ADC values appear relatively high but are of a similar range for all imaged tumors (Figure 2B). Coregistration of hematoxylin & eosin (H&E) histomorphology of tumor sections was achieved using tissue‐inked tumor margins and a standardized trimming protocol. Stainings confirm tissue heterogeneity and cavitations, potentially due to cysts or largely necrotic areas (Figure 2C).
[图:Tumor characterization by DWI and histopathology. (A) Left: Axial anatomical T 2 ‐weighted image of the chest region of ]

Detailed analysis of all neoplasms by experienced veterinary and human pathologists allowed to classify the tumors in this study into two fibrosarcomas (FSs) grade (G)1, seven FS G2, one FS G3, three undifferentiated pleomorphic sarcomas (UPSs), shortly termed pleomorphic sarcomas, one hemangiosarcoma (HAS), one chondrosarcoma (CS), one osteosarcoma (OS), and one “bimorphic tumor” (BMT). For the latter, two distinct morphological growth pattern (GP) compartments were observable, but no precise subtype classification based on H&E and immunohistochemistry was possible due to the lack of feline tissue specific markers. One tumor resection specimen was finally classified as a benign neurofibroma (NF) according to the veterinary WHO classification criteria [45]. Exemplary images of subtype‐specific tumor morphology are summarized in Figure 2D. Notably, all malignant tumors exhibit relatively high ADC values and show no difference between FS grade, while the benign NF reveals the lowest ADC.
[内容请查看原文]
Tumor Acidification
pH imaging using [1,5‐13C2,3,6,6,6‐D4]zymonic acid provided sufficient signal strength, which allowed pH to be mapped in the majority of all imaged tumors with high spatial coverage. This reveals acidified hotspots (Figure 3A), where the mean pH is acidified by up to 0.3 pH units, while most of the tumor area has a physiological pH. These acidified hotspots manifest themselves as acidified pH compartments in the tumor, detectable as an additional spectral peak for the C1‐resonance of zymonic acid (Figure 3B).
[图:pH imaging in vivo reveals tumor acidification. (A) The mean pH map reconstructed from MRSI acquisitions on hyperpolariz]

The corresponding C5‐peak was often not visible due to the lower pH sensitivity and decreased spectral resolution at 3 T compared to higher fields [22]. The additional pH compartment is assigned to the extracellular space [22], while the first compartment originates from tumor vessels. A comparison of absolute pH values of the different tumor groups revealed a decreasing pH with increasing FS grade and tumor pH values being up to 0.2 pH units below the physiological range for many imaged tumors, including the benign NF (Figure 3C). The most aggressive FS G3 exhibits a mean pH below 7.0. In addition, a comparison of tumor pH to healthy tissue pH from the same animals also revealed tumor acidification (pH 7.30 ± 0.18) compared to muscle pH (paired t‐test, pH 7.41 ± 0.11, p = 0.001, Figure 3D). However, the muscle pH values also vary strongly between subjects, and systemic body pH is known to be prone to isoflurane anesthesia [23]. To remove intersubject variations, which can depend on daily animal condition and variations in anesthesia conditions, tumor pH values were subtracted from the respective muscle pH from the same animal to calculate the effective tumor acidification (Ac.). Here, tumor‐adjacent muscle is chosen as the tissue pH reference, as pH values agree with pH values from blood vessel regions (Figure S3), but muscle regions are often closer to the coil and exhibit better signal‐to‐noise ratios. Here, FSs of different grades can show acidification of up to 0.5 pH units (Figure 3E), with a trend to higher acidification for higher FS grade. Bone‐derived sarcomas (CS, OS) also show pronounced acidification, which aligns with previously reported findings [46]. Notably, the HAS and the benign NF show no acidification, potentially either due to strong buffering by blood or non‐malignancy.
[内容请查看原文]
Tumor Metabolism
To probe altered metabolism, hyperpolarized 13C MRSI of [1‐13C]pyruvate and subsequent exchange with [1‐13C]lactate was performed. Time series of pyruvate (top) and lactate (bottom) images showing the first ten frames from a dynamic MRSI acquisition started with a bright bolus in a central blood vessel, followed by strong pyruvate and lactate signal in a central tumor region (Figure 4A). Whole‐tumor time curves (Figure 4B) show a strong pyruvate bolus and corresponding 13C‐labeling of lactate. Using these pyruvate‐ and lactate time curves to calculate area‐under‐the‐curve ratio (AUCr) maps on a voxelwise basis identifies hotspots of high metabolic flux within the tumor region (Figure 4C). Interestingly, qualitative comparison to the pH map in (Figure 3A) shows a similar localization of acidified and metabolically active hotspots. Comparing AUCr values on a whole‐tumor basis (Figure 4D) reveals differences between subtypes similar to the findings from pH imaging and potentially higher metabolic activity for higher FS grade.
[图:Imaging tumor metabolism in vivo. (A) Image time series of [1‐ 13 C]pyruvate and [1‐ 13 C]lactate. The FS G2 shown as an]

UPSs show the highest overall AUCr values but also strong intersubtype variation. The CS turns out to have a markedly higher AUCr value compared to the OS. Similar to the acidification pattern, the HAS and NF show only low metabolic activity relative to the other subtypes.
[内容请查看原文]
Tumor Hypoxia
To investigate the presence of hypoxia in the sarcoma cat patient cohort as a complementary marker to pH and metabolism, [18F]FMISO PET was quantified by two well‐established parameters, namely standard uptake value (SUV) and Patlak‐derived Ki. The former is obtained by summing the last 30 min from the PET acquisition and provides a measure similar to late time point static imaging in clinical settings. The resulting SUV images (Figure 5A) show strong, heterogeneous uptake in the tumors; however, with low contrast compared to directly adjacent muscle tissue. Comparison of the static uptake between tumor subtypes shows substantial variation within the FS groups (Figure 5B). Static uptake in the other subgroups also varies strongly between groups, with the benign NF belonging to the most hypoxic entities. In contrast, UPSs show strong consistency in SUVs for three tumors. The low contrast between muscle and tumor tissue might be explained by the slow washout kinetics of [18F]FMISO. This is indicated by the time activity curves of the tumor and a muscle region (Figure 5C). Here, the kinetics of both tissue types can be clearly distinguished but are not strongly reflected by absolute uptake values within the imaging window. To imprint the kinetic variation into the image contrast, image‐derived arterial input functions (Figure 5D) were used for voxelwise Patlak modeling of the time activity curves.
[图:Tumor hypoxia visualized by the kinetics of [ 18 F]FMISO PET. (A) Exemplary SUV image of a FS G2 summed over the last 30]

The resulting parametric Ki maps show several hotspots of similar location as for the static SUV images; however, with increased contrast compared to the static images (Figure 5E). Interestingly, differences in hypoxia found from SUV for CS, OS, HAS, and NF are not reflected in Ki (Figure 5F). While relative differences between FS grades remain analogous to SUV, the Ki varies stronger within the UPS group compared to SUV. The benign NF shows a high SUV, but only moderate Ki relative to all other subtypes. Validation of hypoxia detection was assessed using pimonidazole, quantified as positive cell fraction on central immunohistochemical sections. SUV shows a slightly stronger, but not significant correlation with pimonidazole positive cell fraction (Figure S4). Overall, all tumors show pronounced hypoxia, exceeding 40% positive cell fraction in all cases.
[内容请查看原文]
Intertumoral Heterogeneity
Following the abovementioned 1D subtype comparisons of just one single parameter, a better understanding of the metabolic processes in sarcomas can be gained by investigating how two or more parameters might be connected to each other. Due to sample size constraints, correlations between imaging biomarkers were only assessed for all tumors and the FS subgroup. Four imaging biomarkers derived from the multimodal imaging protocol (acidification, AUCr, Ki and ADC) were assessed pairwise for correlations. The results are summarized in the correlation matrices involving all tumor subtypes (Figure 6A) and the FS subtypes of different grades (Figure 6B). The matrix involving all subtypes shows a strongly positive correlation (r = 0.71, p = 0.006) between AUCr and Ki, suggesting that metabolic flux from pyruvate to lactate is a result of the low availability of oxygen, potentially reducing the shuttling of pyruvate into the TCA cycle. A similar correlation is found for FSs only, which is not significant (r = 0.50, p = 0.39). Across all subtypes, AUCr also correlates weakly positively with ADC (r = 0.55, p = 0.05), which is opposite for FS (r = −0.39, p = 0.45), and due to two UPS entities of particularly high ADC and AUCr, a respective example is shown in Figure 1A. On the other hand, FSs of varying grade show a strongly positive correlation between lactate labeling and acidification (r = 0.89, p = 0.04), which is even more pronounced for absolute pH and lactate production (r = −0.97, p = 0.008, not shown). The same trend is observed when taking into account all other subtypes, but no significance is reached. Overall, the correlation pattern for FSs as a subtype group and all subtypes is similar. In addition to the absolute mean values, tumor heterogeneity with respect to the examined features can be compared using the mean absolute deviation (MAD). This value reflects the variation across all valid voxels within the tumor for each modality, as tumor heterogeneity cannot be assumed to follow a Gaussian distribution. Here, pH heterogeneity follows a trend similar to absolute acidification, where the most aggressive tumors (FS G3 and UPSs [47]) show the highest heterogeneity with good consistency within subgroups and low heterogeneity for low‐grade and benign tumors (Figure 6C). While a similar trend is observed for metabolic heterogeneity (MAD of AUCr, Figure 6D), variation among UPSs and heterogeneity in the benign NF are increased. Similarly, hypoxic heterogeneity (Figure 6E) also appears to increase with FS grade, which is not seen for ADC heterogeneity (Figure 6F). Notably, some subtypes seem to show comparably high heterogeneity for just one parameter (hypoxia in OS) while others show comparably high heterogeneity for all parameters (e.g., FS G3). Additionally, all parameters (acidification, AUCr, Ki and ADC) can be combined into a 4D feature coordinate. This coordinate can be plotted in a 3D ’metabolic space’ (Figure 6G) where the ADC is color‐coded (CS without valid ADC measurement). Principle component analysis (PCA) on the three spatial dimensions returns an Eigenvector, which suggests that hypoxia, AUCr, and acidification are connected to each other, thereby supporting the suggested functional tumor model (Figure 1A). However, the extent appears to depend on the aggressiveness for the majority of sarcomas, with UPSs deviating most strongly from this finding. A similar pattern can be observed when plotting the MADs in an analogous manner (Figure 6H). While heterogeneity of different metabolic features appears to be linked to each other, tumors of higher aggressiveness, particularly FS, appear at the upper end of this metabolic trajectory, pointing toward sheterogeneity as a potential marker for tumor aggressiveness in FSs.
[图:Intertumoral correlation of metabolic characteristics. Pairwise correlation matrix for six imaging parameters for all tu]

[内容请查看原文]
Intratumoral Heterogeneity
While intertumor correlations provide insight into differences between sarcoma subtypes, intratumoral correlations of parameters provide insight into the metabolic relationships within a single tumor or across the full population subset. For this purpose, imaging parameters were correlated on a voxelwise basis to yield tumor‐specific correlation matrices. An overview of example matrices for each subtype is shown in Figure 7A. Here, patterns show huge variations between subtypes and even among subtypes of varying grades. Nevertheless, it should be noted that analogous to the intertumor correlation, several subtypes show a correlation between pH and AUCr (Figure 7B I, II), which further supports the assumption of a lactate‐driven acidification mechanism. Within the same UPS, lactate metabolism correlates with hypoxia (Figure 7B III). The distribution further indicates that lactate labeling increases in hypoxic areas. However, this observation alone does not establish hypoxia as the cause of the increase in this tumor. Interestingly, some tumors also show unexpected findings. For example, a FS G2 reveals a positive correlation between ADC and Ki, which supports previous findings [48], and counteracts the assumption that dense tumor tissue promotes hypoxia (Figure 7B IV). To further increase insight into metabolic dependencies from the applied imaging modalities, all parameters for each tumor voxel can be plotted as 4D feature coordinates analogous to Figure 6G. Exemplary for a FS G2 (Figure 7C), the tumor voxel distribution aligns along a trajectory in a 3D subspace, which can be visualized by a PCA‐derived trajectory (red). This suggests a mechanistic relation between hypoxia, subsequently altered metabolism, and resulting extracellular acidification. Further, higher ADC values appear to be related to lower pH, higher AUCr, and increased Ki. To facilitate cross‐tumor comparison, PCA was repeated using z‐scores for all parameters, thereby mitigating scale effects and enabling direct assessment of parameter dependencies across tumors. Plotting the corresponding unit vectors, analogous to Figure 7C, yields a distribution of ‘metabolic vectors’ that characterizes the relationships between the metabolic parameters within each tumor (Figure 7D). Weakly aggressive tumors (FS G1, NF) show little or no acidification potential (Δz(pH) ∼ 0 or Δz(pH) < 0) in contrast to many aggressive tumors (FS G2, FS G3, UPS). The extent to which each tumor relies on anaerobic glycolysis for extracellular acidification is quantified by the PMH score (Experimental Section ‘Statistics and Principal Component Analysis’; Figure 7E). Consistently, FS G2, FS G3, and UPS, which are among the most aggressive tumors in our cohort, exhibit the highest scores compared to low grade (FS G1) or benign tumors (NF). Despite the acquisition of four imaging biomarkers, the cumulative explained‐variance plot suggests that the heterogeneity of most tumors can be described by only two principal components, which account for more than 80% of the variance in almost all tumors (Figure 7F). An exemplary biplot (Figure 7G; same subject as in Figure 7C), visualizing the relationships between principal components and measured parameters, shows that pH and AUCr derived from hyperpolarized 13C MRSI contribute most strongly to the observed heterogeneity. From a practical viewpoint, it would be interesting to reduce the number of imaging modalities while still assessing intratumoral heterogeneity in its full complexity. From subset‐based PCA analysis determining the two most heterogeneity‐capturing modalities, all four modalities appear to be of similar importance when assessing how often each modality belongs to the two modalities that describe most of the heterogeneity within one tumor entity (Figure 7H top). Clinically, instead of employing two imaging modalities, it is even more of interest to identify the single most informative modality if acquisition had to be limited to one. Based on a second corresponding subset analysis, AUCr derived from hyperpolarized 13C MRSI of [1‐13C]pyruvate can be identified as the most informative modality (Figure 7H bottom).
[图:Intratumoral correlation of metabolic characteristics. (A) Representative correlation matrices for all tumor types and g]

[内容请查看原文]
Patient Case ‐ Bimorphic Tumor
A particular case in this study was the finding of a bimorphic tumor, which presents histopathologically with two distinct morphological GPs. In the respective patient, the tumor looped around the right hindlimb and presented with an acidified hotspot in the pH map, complementary to another, dislocated hotspot of high metabolic flux and strong [18F]FMISO uptake. In contrast, anatomical images and the ADC map were inconclusive (Figure 8A). Upon resection and histological assessment by H&E (Figure 8B left), the tumor entity turned out to consist of two histomorphologically different compartments with distinct cellular GP (GP1 and GP2). However, neither H&E nor various applied immunohistochemical markers (section ‘Tumor Morphology’) allowed the unambiguous assignment of these GPs to a distinct sarcoma subtype. Staining for pimonidazole shows a slightly increased positive tissue fraction for GP2 (Figure 8B right) in line with strong PET uptake. Coregistration and ROI transfer from histology to the imaging modalities indicate the distinct hotspots to correspond to the different tumor compartments (Figure 8A insets). Intratumor correlation analysis analogous to Figure 7A clearly distinguishes the GP1 from the GP2 compartment (Figure 8C). Notably, the matrix pattern of the GP2 compartment matches overall findings for the FS subtype in Figure 6B and Figure 7A.
[图:Multimodal imaging reflects tumor compartmentation in a bimorphic tumor. (A) In contrast to anatomical images, parameter]

Further, both compartments show clearly distinguishable ’glycolytic vectors’, which indicates the possibility for non‐invasive differentiation of the compartments by multimodal imaging (Figure 8D). To assess the distinguishability of both compartments based on the applied imaging modalities, histograms of all voxels with assigned compartments were generated (Figure 8E). Here, pH allows a clear separation of both compartments (p < 0.0001) while metabolism also reliably differentiates between the compartments (p = 0.006). In contrast, PET parameters, namely Ki and SUV, as well as ADC, fail to distinguish the voxel populations, suggesting a high value for hyperpolarized 13C MRSI for characterization of intra‐ and intertumoral metabolic heterogeneity.
[内容请查看原文]
Prognostic Potential of Multimodal Imaging
The ability of each imaging biomarker to assess patient outcome was assessed by a follow‐up survey up to four years after study initiation (Figure S5). Stronger hypoxia, indicated by either increased SUV (Figure 9A) or Ki‐values (Figure 9B) points toward reduced median survival, but is not conclusive. Interestingly, higher ADC values appear to be related to a more than four‐fold reduced median survival (Figure 9C), however without reaching significance. The same holds for hyperpolarized 13C MRSI, where higher metabolic flux of pyruvate to lactate (Figure 9D) shows a trend to a strongly reduced median survival.
[图:Kaplan–Meier survival analysis using imaging parameters. Survival curves from dichotomized groups for static (A) and kin]

For pH imaging, normalization of pH is important, as absolute pH (Figure 9E) does not allow for a clear distinction of patient groups. In contrast, acidification beyond 0.1 pH units is suggested to be a suitable cutoff, as it distinguishes a 3.8‐fold reduction of median survival (Figure 9F) and is therefore the most relevant prognostic imaging parameter within our small cohort study. Increased hypoxia, higher ADC, high metabolic activity, and strong acidification are unfavorable tumor characteristics as shown by group dichotomization. This is also reflected in a direct correlation analysis of overall survival duration and the respective parameters (Figure S6). In this case, acidification, metabolism and ADC exhibit the strongest correlations with overall survival, with the strongest acidified tumors resulting in the shortest survival times. Additionally, to assess potentially confounding factors, tumor volume, age, weight, sex, breed, and tumor location as meta parameters from Table S1 were assessed for their predictive potential (Figure S7A–F). None of them appears relevant to predict outcome of the cats within our cohort. Correlation of continuous meta parameters age, weight and tumor volume indicates a negative correlation of age with SUV and volume, while volume correlates positively with ADC and AUCr (Figure S7G). Categorical meta parameters show no relevant confounding influence on imaging parameters (Figure S7H), but interestingly, tumors located on the abdominal wall show a significantly lower acidification (mean ΔpH = 0.05) compared to tumors located on other parts of the body (mean ΔpH = 0.19, Figure S7H).
[内容请查看原文]
Discussion
This study set out to establish a clinically relevant workflow for simultaneous assessment of extracellular pH, metabolism, and hypoxia on a 3 T clinical PET/MRI system, using hyperpolarized 13C MRSI of pH alongside hyperpolarized [1‐13C]pyruvate MRSI and [18F]FMISO PET in spontaneous feline tumors. One of the challenges in the clinical translation of novel MRI techniques is moving from preclinical scanners, mostly operating at 7 T and beyond, to a clinical 3 T system. Here, spectral resolution is lower, which complicates spectral assignments, in particular for assessing pH. However, at 3 T compared to 7 T, there is also the benefit that 13C T 1 relaxation time constants of pyruvate and zymonic acid are prolonged [44], which results in a longer availability of hyperpolarized magnetization and therefore better signal‐to‐noise ratio. Here, the technical feasibility, particularly the scaling of the hyperpolarization protocols to a clinical setting, and sound measurement accuracy could be demonstrated based on a comprehensive set of feline patient data. This clearly shows that chemical shift–based pH mapping using probes such as [1,5‐13C2,3,6,6,6‐D4]zymonic acid yields robust, spatially resolved readouts in a clinical setting. Together, these findings support the premise that hyperpolarized 13C pH imaging is not only technically viable but also holds value for further translational development.
Even though blood counting and animal monitoring indicated good tolerability of the injections and imaging procedures in this study, dedicated toxicology and development of sterile compounding workflows will be essential for clinical translation of [1,5‐13C2,3,6,6,6‐D4]zymonic acid. In contrast, [1‐13C]pyruvate has already been used in clinical trials [20], and [18F]FMISO is established in clinical practice at some centers, which lowers the barrier for future human implementation of the proposed combined protocol [19].
A key motivation for simultaneous, coregistered mapping of hypoxia, metabolism, and extracellular pH is tumor heterogeneity as these parameters can vary substantially within a lesion and sequential measurements complicate spatial correspondence and mechanistic interpretation. In this study, spontaneous feline tumors served as an intermediate model between rodents and humans, as they represent morphologic features of similar human neoplasms and are more comparable in both size and basal metabolic rate to human counterparts, which highlights the potential and applicability of spontaneously arising neoplasms in pets in comparative biomedical studies [49]. The high inter‐ and intratumoral variability observed within this study cohort emphasizes this point. At the same time, the modest cohort size and limited numbers per histologic subtype require cautious interpretation, particularly for claims about subtype‐specific biological mechanisms.
Interestingly, DWI resulted in comparably high ADC values (1.79–2.91 ∙ 10−3 mm2/s) for the entire study cohort. Similarly high values have been found previously [50] for benign and malignant soft tissue tumors, among which were sarcomas. However, lower values are often observed for malignant lesions (0.87–1.40 ∙ 10−3 mm2/s) [51] and, in particular, soft tissue sarcomas (0.47–2.09 ∙ 10−3 mm2/s) [52, 53, 54], with strong heterogeneity for the latter due to varying cellularity, extracellular matrix composition, necrosis, and edema. pH and metabolic imaging point out potential differences between subtypes investigated in this study. pH imaging using 13C‐labeled, deuterated zymonic acid as a probe was demonstrated for the first time in cats. While pH measurements in this study were not validated by gold standards such a blood gas analysis or any other imaging readouts such as 31P MRSI or CEST, zymonic acid as a pH sensor was carefully validated against other techniques in previous studies [22]. pH imaging in this work revealed pronounced acidification hotspots in tumors and overall tumor acidification for several subtypes. Nevertheless, mean pH values reported in this study contain weighting from non‐acidified vessel compartments, which explains why absolute pH values found in this study appear less acidified compared to previous studies of sarcoma pH [55, 56, 57]. Observed tumor acidification aligns with previous findings from canine sarcoma patients, where tumor acidification was observed to be an indicator of aggressiveness and poor prognosis [58]. While UPSs are generally considered highly aggressive [47], OS and CS have already been suggested to acidify their extracellular space via an increased expression of CAIX and vATPase [46]. This matches our observation of strong acidification and low metabolic flux in the OS case of this study. This observation supports the rationale for measuring pH directly rather than inferring it from metabolism alone.
AUCr values to quantify metabolism in this study also indicated strong metabolic flux from pyruvate to lactate in most sarcoma cases, albeit with marked heterogeneity across tumors and within lesions. AUCr‐based quantification provided a practical summary metric for the present acquisition given the low temporal resolution and the limited number of signal‐containing data points. However, variability might be reduced by kinetic modeling of dynamic imaging data [59] and acquisition at higher spatial and temporal resolution [60, 61]. Even with these limitations, the observed lactate production is consistent with the broader concept of metabolic rewiring in sarcomas [62]. One reason might be that despite an increased need for glucose and oxygen consumption, glucose oxidation was found to be impaired in sarcomas [63].
PET imaging of [18F]FMISO could be well integrated into the hyperpolarized 13C MRSI workflow, enabling additional hypoxia imaging within the imaging session. Arterial input function quantification suffered from the insertion of the dual‐tuned MRI coil during the PET acquisition, which induced further attenuation. However, neither kinetic modeling nor static averaging of late time points are notably affected by this technical burden, as coil insertion took place after the input function peak and prior to the tumor time activity curve section which was used for modeling. Hypoxia was indicated by elevated SUV and Ki values compared to healthy tissue and corroborated by pimonidazole staining, which matches previous studies of PET‐based hypoxia imaging in feline sarcoma patients [64, 65]. Unexpectedly, correlation of pimonidazole analysis and PET parameters remains limited, potentially due to different scales and slice thicknesses—consistent with known challenges in quantitatively linking PET hypoxia tracers to ex vivo hypoxia markers [66]. While SUV shows a slightly stronger correlation with pimonidazole compared to Ki, the prognosis and therapy outcome have been shown to be indifferent between parameters [67]. Similar to our results, clinical studies enrolling sarcoma patients for [18F]FMISO PET point toward a relation between sarcoma aggressiveness and hypoxia, but evidence for this is still in its infancy [65, 68].
While PET hypoxia biomarkers were not conclusive as a predictor for patient outcome in this study, intratumoral heterogeneity is best captured by metabolic imaging using [1‐13C]pyruvate. Tumor acidification measured by hyperpolarized 13C MRSI of pH using [1,5‐13C2,3,6,6,6‐D4]zymonic acid turned out to be a promising predictive biomarker for patient outcome among all investigated parameters. This is consistent with the clinical motivation which assumes that extracellular acidity shapes antitumor immunity and may represent a modifiable vulnerability. If confirmed in larger studies, pH imaging could complement hypoxia and metabolic readouts for stratification and therapy monitoring, and could help identify tumors most likely to benefit from microenvironment‐targeted conditioning strategies.
One major limitation of this study is the low number of patients for each subtype, several of them including only one patient case. Further, as has been shown for the bimorphic tumor, subtype differentiation, even with comprehensive histopathology, is not always possible in veterinary patients. A main challenge here is the limited availability of feline species‐specific immunohistochemistry markers in contrast with human diagnostics. This restricts the ability to further characterize compartmental subtypes based on imaging. In addition, collecting all data with sufficient quality to perform multi‐parameter analysis is challenging and requires initial experience and optimization. This further limits the number of complete datasets.
Prior to this work, studies had already been conducted using combined hyperpolarized 13C MRSI and PET. These found correlations between lactate production and [18F]FDG [30] and further allowed to differentiate between bone sarcomas and soft tissue sarcomas in canine cancer patients [31]. Within these, also differences in correlation of the main parameters k pl and FDG uptake were observed between subtypes. However, no general pattern across different tumors was found, confirming the high diversity and metabolic complexity of sarcomas. Similar results were also found in a study in rats [27], where cellularity and necrosis were considered to be important, potentially confounding factors. In addition, a combination of multiple modalities might be more reliable in better assessing early therapy response [69]. Beyond hyperpolarized [1‐13C]pyruvate and [18F]FDG, which are sometimes considered to be in competition [70], truly complementary imaging in a multimodal setting has already been performed to assess metabolism in conjunction with vascularization or receptor expression [32, 33]. Moreover, in particular PET/MRI has been shown to be of great value in understanding complex diseases and exploiting the versatility of multimodal imaging by combining PET and functional MRI in Alzheimer's disease [71, 72, 73]. The advances in imaging hardware development over the last decades led to the emergence of a variety of powerful multimodal devices. These range across scales from in vitro platforms working on a single‐cell level [74] to clinical routine in humans [75]. PET and molecular imaging by MRI are sometimes considered to be opponents in the dominance for disease diagnosis and therapy decision making. Instead, it becomes clear that a multimodal approach exploiting their complementarity provides additional value for diagnosis and therapy response assessment.
[内容请查看原文]
Conclusion
In summary, this work advances translational multimodal imaging by implementing a single‐session, clinically realistic protocol on a 3 T PET/MRI system that simultaneously measures hypoxia ([18F]FMISO), metabolic flux (hyperpolarized [1‐13C]pyruvate), and extracellular pH (hyperpolarized [1,5‐13C2,3,6,6,6‐D4]zymonic acid). Feline sarcomas offer a pragmatic bridge between rodent studies and human application by enabling evaluation of feasibility, co‐localization, and heterogeneity in a clinical workflow setting. Notably, pH mapping proved to be of value for characterizing intra‐ and intertumoral heterogeneity and predicting patient outcome. If validated in larger cohorts, this approach could support biomarker development for stratification and therapy monitoring.
[内容请查看原文]
Experimental Section
[内容请查看原文]
Study Design and Workflow
In this study, the feasibility and tolerability of simultaneous hyperpolarized 13C MRSI and PET were assessed to study hypoxia, metabolism, and tumor acidification in direct comparison. The experiments were performed according to pertinent laws and regulations and approved by an ethical review board (Regierung von Oberbayern, ROB‐55.2‐2532.Vet_02‐17‐177). Patients were recruited via a newsletter that was sent to a large number of veterinary practices in Bavaria, Germany. Pet cats whose owners expressed interest in the study and provided written informed consent, and which had a palpable mass underwent a biopsy, a blood count, a cardiopulmonary check, and an ultrasound exam. Inclusion criteria were a confirmed, curatively resectable malignant mesenchymal mass of at least 2 cm in palpable diameter. Recurrent or metastatic tumors were exclusion criteria. Prior to the multimodal imaging protocol, written informed consent on risks and conditions of the study was collected from the owners. The age, sex, breed, and weight of all included patients are listed in Table S1. Blood counting was performed directly before and after imaging to assess immediate adverse side effects. Animals were weighed, handled, and monitored continuously by at least one experienced veterinarian at all times during the imaging session. For the injection of imaging agents, a catheter was placed in one of the forelimbs. Anesthesia was initiated by intravenous injection of propofol. Cats were intubated, and anesthesia was maintained by controlled ventilation using isoflurane (0.8%–2.8%) with oxygen‐enriched (40%) medical air as carrier gas. Body temperature was maintained by blowing warm air into the bore (Mistral air, The 37C Company, Amersfoort, Netherlands). Rectal temperature was monitored using an MR‐compatible temperature monitoring system Model 1030 (SA Instruments, Stony Brook, USA). Heart rate and peripheral blood oxygenation (SpO2) were monitored using a MR‐compatible patient monitor (Expression MR Patient Monitor, Invivo, Gainesville, USA). Additionally, end‐tidal CO2 (EtCO2), inspiratory peak pressure, and respiratory minute volume were continuously monitored. Following imaging and patient wake‐up, cats were returned to their owners in accordance with radiation protection regulations. For surgery planning, anatomical MR images were diagnosed by experienced clinical human radiologists and veterinary radiologists. All cats underwent surgery for tumor removal, generally 3–5 days post imaging and received no further tumor‐related treatment within the follow‐up period. Resected tumor specimens were histopathologically evaluated to confirm complete tumor removal (R0 status). After histopathological workup, all resected tumors were microscopically evaluated by experienced pathologists. A complete list of tumor types, locations, extensions, and volumes is provided in Table S1.
[内容请查看原文]
Hyperpolarization
For pH imaging, 213.4 mg [1,5‐13C2,3,6,6,6‐D4]zymonic acid (synthesized in‐house) [44] was mixed with 8.5 mg OX063 trityl radical (GE Healthcare, Chicago, USA) and added to 190 µl dimethyl sulfoxide. The mixture was vortexed for 90 min, transferred to a DNP sample cup, and frozen in liquid nitrogen. For co‐polarization with [13C]urea, 135 µL of a 10 m [13C]urea in glycerol containing 30 mm OX063 was added, and the sample cup was again frozen in liquid nitrogen. The sample was then polarized by DNP in a HyperSense DNP polarizer (Oxford Instruments, Abingdon, UK) at a microwave frequency of 94.190 GHz and 100 mW power for at least 3–4 h. Having reached saturation polarization, dissolution was performed using 9 mL dissolution agent being heated to 180°C. It consisted of 7.65 mL D2O containing 80 mm tris(hydroxymethyl)aminomethane (TRIS), 0.1 g/L Na2‐ethylenediaminetetraacetic acid (EDTA), to which 1.35 mL 1 m NaOH in D2O was added. The resulting injection solutions contained concentrations of 150 mm zymonic acid and 150 mm urea with pH 8.08 ± 1.78. For imaging metabolism, 96 µL of a solution containing 14 m [1‐13C]pyruvic acid (Sigma–Aldrich, St. Louis, USA), 15 mm OX063 and 1 mm DOTAREM (Guerbet, Villepinte, France) was added to a DNP sample cup and polarized by DNP in a HyperSense DNP polarizer at a microwave frequency of 94.190 GHz and 100 mW power for at least 30 min. The sample was dissolved using a mixture of 8.307 mL H2O buffered with 80 mm TRIS and 0.1 g/L Na2EDTA and 0.693 mL 1 m NaOH in H2O. The resulting injection solutions contained 150 mm pyruvic acid with pH 6.06 ± 1.73.
[内容请查看原文]
Imaging Protocol
Imaging was performed on a clinical 3 T PET/MRI scanner (Biograph mMR, Siemens Healthcare, Erlangen, Germany) using syngo VE11P service pack 3. Following the initiation of anesthesia, cats were centered with the tumor pointing downward on an in‐house‐built bed mounted on the patient bed of the clinical scanner. Initial localizer scans, attenuation maps, and whole‐body 3D imaging (Experimental Section ‘Anatomical MRI’) were acquired using the scanner's body coil. For subsequent 13C MRSI (Experimental Section ‘13C MRSI’), a dual‐tuned flexible 1H/13C Tx/Rx surface coil with 21 cm × 32 cm cross section (Rapid Biomedical, Rimpar, Germany) was inserted on the cat bed rail system to place the coil directly under the tumor without moving the cat.
[内容请查看原文]
Anatomical MRI
Initial patient positioning was verified using a standard localizer sequence. Parallel to start of the PET acquisition, a standard generalized autocalibrating partially parallel acquisitions (GRAPPA)‐based 3D fast low‐angle shot (FLASH) two‐echo Dixon sequence [76, 77, 78] with matrix 126 × 192 × 128, resolution 2.64 × 2.64 × 3.12 mm3, TR 3.56 ms, TE 1.23 ms, total acquisition time 31.34 s was used for fat‐water‐based attenuation mapping. Whole‐body 3D imaging for primary tumor localization and detection of potential additional lesions used a 3D magnetization‐prepared rapid gradient echo (MPRAGE) sequence with typical parameters being matrix 120 × 320 × 192, resolution 0.5 × 0.5 × 1 mm3, TR 2050 ms, inversion time (TI) 1040 ms, TE 4.16 ms, 4 averages, total acquisition time 8 min 11 s. A second 3D sequence, namely, a 3D fluid‐attenuated inversion recovery (FLAIR) was acquired with typical parameters being matrix 144 × 384 × 192, resolution 0.83 × 0.83 × 1 mm3, TR 3000 ms, TI 1800 ms, TE 393 ms, echo train length 258, 4 averages, total acquisition time 8 min 21 s. Additionally, for MRSI slice positioning, axial, sagittal, and coronal 2D FLASH T 1‐weighted images with typical parameters being matrix 216 × 384 × 35, slice thickness 3 mm, resolution 0.41 × 0.41 × 3 mm3, TR 250 ms, TE 2.84 ms, 12 averages, total acquisition time 4 min 47 s were acquired. For anatomical coregistration for MRSI slices, T 2‐weighted images using half‐Fourier acquisition single‐shot turbo spin echo imaging (HASTE) with matrix 144 × 384 × 3, slice thickness 3 mm, resolution 0.41 × 0.41 × 3 mm3, slice spacing 4.98 mm, TR 2000 ms, TE 49 ms, 32 averages, total acquisition time 3 min 6 s were acquired.
[内容请查看原文]
13C MRSI
Shimming was performed using the routine user‐interactive map shim tool and the 13C frequency was calibrated using an 8 M [13C]urea phantom doped with Gd‐DOTA. The coil reference voltage was manually adjusted by searching for the reference voltage returning the highest 13C signal in single 13C spectra of the urea phantom. For hyperpolarized imaging of pH, cats were injected with 8 mL of hyperpolarized zymonic acid‐urea solution, with injections starting 38 ± 3 s post dissolution and injection duration 14 ± 2 s. Free induction decay chemical shift imaging (FIDCSI) for pH imaging was started with the end of injection using a 15° flip angle, matrix 8 × 16 with elliptical k‐space encoding, FOV 80 × 160 mm2, slice thickness 13 mm, in‐plane resolution 10 × 10 mm2, TR 156 ms, spectral receive bandwidth 4000 Hz, 256 spectral points, acquisition time 10.14 s as typical parameters. For hyperpolarized imaging of pyruvate‐lactate label exchange, 8 mL of hyperpolarized pyruvate solution were injected 38 ± 6 s post dissolution and injection duration 14 ± 3 s at a delay 55 ± 11 min post zymonic acid injection. Dynamic CSI used the same parameters as for hyperpolarized imaging of pH, except being acquired for a total of 2 × 8 frames, leading to 16 frames overall with a typical temporal resolution of 10.14 s and total acquisition time of 162.24 s. Acquisition started with the start of injection.
[内容请查看原文]
Diffusion‐Weighted Imaging
DWI used a standard 2D echo‐planar imaging (EPI) sequence ’ep2d’ with typical parameters being: matrix 60 × 128 × 3, slice thickness 3 mm, resolution 1.5 × 1.5 × 3 mm3, slice spacing 4.98 mm, TR 3000 ms, TE 49 ms, 4 averages, total acquisition time 7 min 36 s. For diffusion encoding, 8 b‐value (0, 50, 100, 200, 300, 500, 800, 1000 s/mm2) images were acquired, the latter two being averaged 8‐fold. b‐value images were fitted voxelwise using a mono‐exponential with offset to derive ADC values. Voxels with less than the two‐fold median signal intensity and non‐converging ADC fits in the range 0–5·10−3 mm2/s were discarded.
[内容请查看原文]
PET Imaging
For PET imaging, PET data were acquired as a large list mode file for a total of 180 min. Due to file size constraints, the PET acquisition was split into a first block lasting 60 min and a second block lasting 120 min. Acquisition started right before injection of 149.7 ± 7.6 MBq [18F]FMISO dissolved in 2 mL citrate‐free solution (ABX, Radeberg, Germany). PET images from both blocks were reconstructed separately using the GRAPPA attenuation map and framing: 20 × 3 s, 12 × 5 s, 26 × 30 s, 3 × 300 s, 3 × 600 s for the first block and framing: 12 × 600 s for the second block. Digital imaging and communications in medicine (DICOM) images from both blocks were merged into one joint series using an in‐house written Python script.
[内容请查看原文]
Histopathology
One hour prior to surgery, cats were injected with 0.3 g/m2 pimonidazole (Hypoxyprobe Inc., Burlington, USA) for immunohistochemical visualization of hypoxia. Following surgery, tumors were marked with tissue ink of various colors to encode absolute orientation and properly fixed in formalin (1:10 tissue:formalin ratio). For coregistration with imaging data, tumors were cut into 0.5 cm thick slices according to the 13C MRSI slice orientation and smaller patches for each slice to fit histology cassettes (41 mm × 27.5 mm × 12 mm, Carl Roth, #EE16.1). Tumors were then stained with H&E according to a standard protocol. Fluorescein isothiocyanate (FITC)‐labeled anti‐pimonidazole antibody (Hypoxyprobe Inc., #HP2‐1000Kit, primary antibody: Lot# 05.18.18, secondary antibody: Lot# 08.23.18) followed by a horseradish peroxidase (HRP)‐conjugated anti‐FITC secondary antibody was used in order to immunohistochemically visualize and confirm tissue hypoxia detected by [18F]FMISO PET. Submitted routine diagnostic samples of feline FSs from cat patients not undergoing pimonidaziol injection were used as negative controls (Figure S3). Based on H&E histomorphology and, if applicable, immunohistochemical marker profile, tumors were then classified according to the current veterinary WHO classifications and veterinary pathology standards [45, 79, 80]. Furthermore, FSs were graded (G1 = low grade, G2 = intermediate, G3 = high grade) according to a grading guideline for feline FSs [40].
[内容请查看原文]
Blood Counting
For each patient, at least two blood samples (one prior and one post imaging) and up to four blood samples were drawn into S‐Monovette EDTA K3E (Sarstedt, Sarstedt, Germany). Blood counting was performed using a Sysmex XT‐2000iVet (Sysmex, Kobe, Japan). Blood serum was analyzed using a Roche Cobas Integra 400 plus (Roche, Basel, Switzerland).
[内容请查看原文]
Follow‐Up Survey
To assess patient outcome following surgical tumor removal, a follow‐up survey was conducted to interrogate for subsequent treatments related to the diagnosed tumor, recurrence, and survival status. For this purpose, cat patient owners were contacted via phone between July 2024 and September 2024. The survey form is displayed in Figure S5. The survey was completed by nine cat patient owners, and overall survival for one patient was obtained from a follow‐up visit at the Centre of Clinical Veterinary Medicine. For survival analysis, patients with follow‐up information were dichotomized into favorable and unfavorable prognosis groups. To determine the optimal parameter‐specific cutoff value, ROC curve analysis was performed for three different time points (6, 12, 18 months), and optimal cutoffs were selected for each ROC curve by calculating the Youden index. Derived cutoff values were then averaged across all three time points to yield the final cutoff value. Significance, determined by p values ≤ 0.05, was tested using the Mantel‐Cox test.
[内容请查看原文]
Data Analysis
Generation of scripts in MATLAB (The MathWorks, Natick, USA) was assisted by a large language model (ChatGPT, OpenAI, San Francisco, USA). No blinding was applied at any stage because of the explorative nature of this pilot study. For coregistration of all imaging modalities, DWI and PET images and related parametric maps were downsampled to match the resolution of the four‐fold interpolated 13C acquisitions.
[内容请查看原文]
pH Map Reconstruction
For the reconstruction of pH maps, raw data files were exported via TWIX. All post‐processing was performed in MATLAB 2022b using a graphical user interface (GUI) platform similar to the one described previously [23]. In detail, CSI raw data was zero‐filled by a factor of 2 in spectral dimension, interpolated by a factor 4 in spatial directions, and line broadened by 6 Hz. For pH fitting, [13C]urea and up to four zymonic acid peaks (C1 and C5) were searched for. The latter correspond to two compartments, with compartment ranges being 7.25–7.9 and 6.6–7.25 based on previous findings [22, 23], with a minimum signal‐to‐noise ratio (SNR) of 20 relative to apodized spectra edges. pH values were fitted from peak positions relative to urea using the reported calibration curve [22]. For voxels containing more than one pH compartment, mean pH values, only reported as pH throughout this study, were averaged using the peak intensities as weights. Tumor mean pH values were averaged across the whole‐tumor ROI. Acidification ΔpH was defined and calculated by subtracting the tumor pH (pHtumor) from the pH of an adjacent muscle region (pHmuscle) within the same subject and serves only for intertumor comparison: ΔpH=pHmuscle−pHtumor
[内容请查看原文]
Quantification of Pyruvate‐Lactate Label Exchange
For quantification of pyruvate‐lactate label exchange, raw data files were exported via TWIX. All post‐processing was performed in MATLAB 2022b using a GUI platform similar to the one described previously [23]. In detail, CSI raw data was zero‐filled by a factor of 2 in spectral dimension, interpolated by a factor 4 in spatial directions, and line broadened by 6 Hz. [1‐13C]Pyruvate and [1‐13C]lactate peak positions were integrated over a range of 16 Hz, and the resulting time curves were baseline‐corrected. Pyruvate and lactate time curves were then summed over time, and the cumulative lactate signal was divided by the cumulative pyruvate signal to obtain AUCr values. Voxels with a pyruvate peak SNR of less than 5 were excluded.
[内容请查看原文]
Quantification of Hypoxia
Quantification and post‐processing of PET data were done using Inveon Research Workplace 4.2 (Siemens Healthineers, Erlangen, Germany). PET images, anatomical 3D and 2D MRSI‐volume matching MR images were imported, and coregistration manually fine‐adjusted if necessary using rigid rotation or translation. PET signal intensities were converted to SUVs, and intensity values from the last 30 min, corresponding to three frames, were averaged. This derives a static late uptake value as a measure for hypoxia as commonly used in clinical studies [81]. As a second measure to quantify hypoxia, late uptake phases, which show linear uptake kinetics, were modeled using the Patlak model [82]. For pharmacokinetic modeling, regions of interest were drawn on a vena cava segment close to the tumor location, and the extracted time curves served as image‐derived input functions for modeling. Using this input function and the dynamic curves from t = 60 min to t = 180 min (second acquisition block) for voxelwise kinetic modeling yielded kinetic uptake rate (Ki) maps, where positive values indicate an increasing degree of hypoxia [66].
[内容请查看原文]
Quantification of Immunohistochemical Staining
Scanned slides were analyzed in QuPath 0.5.1 [83]. First color deconvolution was achieved by adjusting staining vectors for diaminobenzidine and haematoxylin separately for each slide individually using strongly positive and negative section regions. Calculation of the hypoxia‐positive cell fraction was performed using the built‐in positive cell detection algorithm with a binary threshold. The binary threshold was determined by control classification on positive and negative control sections. Detection and classification parameters for each immunohistochemical staining are listed in Figure S4G.
[内容请查看原文]
Statistics and Principal Component Analysis
Statistical analysis was performed using GraphPad Prism 7 (GraphPad Software, San Diego, USA), and two‐sided t‐tests or Mann–Whitney U‐tests were used depending on whether datasets were normally distributed. Two‐parameter linear regression analysis was performed in Origin 2018b (OriginLab, Northampton, USA). Values of p ≤ 0.05 were considered statistically significant. For intertumor correlation matrices, whole‐tumor mean parameter values or individual voxel parameters were plotted pairwise and fitted using linear regression. For intratumoral correlation analysis, ADC values were summed voxelwise across all three imaged slices, and PET and DWI parametric maps were resampled to match the resolution of the interpolated 13C parameter maps. For multidimensional analysis of parameter relationships, PCA was performed using the built‐in MATLAB algorithm on either three (pH/Ac., AUCr, SUV) or four (pH/Ac., AUCr, SUV, ADC) parameters for subjects with a complete set of valid imaging data. For qualitative visualization of general parameter dependencies, non‐standardized parameters were used, and the first eigenvector axis was displayed (as shown in Figure 7C). For quantitative analysis (Figure 7D–H), z‐scores [84, 85] were calculated for each parameter using a global median and interquartile range across all tumors. To assess the degree of hypoxia‐driven lactate metabolism and the associated extracellular acidosis within a tumor, a ‘pH‐metabolism‐hypoxia (PMH) score’ was defined as the absolute value of the dot product between the first PCA vector and a normalized ‘Warburg vector’ W = [‐1, 1, 1]/3.
[内容请查看原文]
Subset‐Based PCA Analysis of Intratumoral Heterogeneity
To identify the two or single most informative imaging modality for capturing tumor heterogeneity, a projection‐based subset evaluation approach inspired by the principal variables concept was used [86, 87, 88]. To determine the single most descriptive modality, for each tumor, each parameter (pH, AUCr, Ki, ADC) was evaluated separately with respect to its ability to preserve the dominant multivariate heterogeneity pattern defined by PCA of the full parameter set within a tumor. For this purpose, 5‐fold cross‐validation was performed by partitioning the voxel data of each tumor into five approximately equal subsets. In each iteration, four of these fractions Sfit were used to perform a linear least‐squares regression with offset of the included PCA scores Sfit and the z‐scores of the tested modality, and the remaining subset Stest was held out for testing.
The fitted regression coefficients were then applied to the held‐out test subset to predict the corresponding PCA scores S^test. The predictive accuracy was quantified using the coefficient of determination: R2=1−SSESST where SSE=∑Stest−S^test2 is the residual sum of squares between true and predicted PCA scores in the test subset, and SST=∑Stest−S¯fit2 is the total sum of squares relative to the mean PCA score of the subsets for fitting. This procedure was repeated five times so that each subset served once as test data, and the resulting R 2 values were averaged. The modality with the highest mean R 2 was considered to best preserve the dominant PCA‐defined heterogeneity structure of the tumor. To determine the two most descriptive modalities, the same workflow as for one modality was applied but employing the z‐scores from two modalities for linear regression. The analysis was repeated for all pairs of parameters, and the best pair was determined from the largest value of R 2 across all parameter pairs within a tumor.
Author Contributions
Conceptualization: MS, KS, AML, JH, CB, FS. Methodology: MG, TG, SB, JC, MS, KS, AML, JH, FS. Investigation: MG, TG, SK, SB, EB, FHAvH, PW. Formal analysis: MG, TG, AW, JC, SN, CL, KS, FS. Visualization: MG, TG, FS. Funding acquisition: MS, WW, KS, AML, JH, CB, FS. Project administration: WW, KS, AML, JH, CB, FS. Supervision: JH, FS. Writing – original draft: MG, TG, FS. Writing – review and editing: MG, TG, AW, PW, FS.
Funding
This research was funded by Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, Sonderforschungsbereich (SFB) 824, subprojects A7, Z2 and Z3, the Emmy Noether programme grant number 391523415 (MS, WW, KS, FS). Young Academy of the Bavarian Academy of Sciences and Humanities (FS). European Union's Horizon 2020 research and innovation program under grant agreement No 820374 (FS). German Federal Ministry of Research, Technology and Space (BMFTR) in the Funding Program ’Quantum Technologies – from Basic Research to Market’ Under the Project ’QuE‐MRT’, contract number: 13N16450 (FS).
Conflicts of Interest
FS serves on the scientific advisory board of NVision Imaging Technologies GmbH.
Supporting information
[内容请查看原文]
兽研